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Vaccines preparations against canine parvovirus are pro-
vided. The vaccines include a novel canine parvovirus-2 iso-
lated from a raccoon, and related nucleic acids and proteins. 
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(SEQ ID NO : 1 ) 
Figure 2A 

































(SEQ ID NO: 2) 
Figure 2B 
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Met Ser Asp Gly Ala val Gln Pro Asp Gly Gly Gln Pro Ala val Arg 
1 5 10 15 
Asn Glu Arg Ala Thr Gly Ser Gly Asn Gly Ser Gly Gly Gly Gly Gly 
20 25 30 
Gly Gly Ser Gly Gly val Gly Ile Ser Thr Gly Thr Phe Asn Asn Gln 
35 40 45 
Thr Glu Phe Lys Phe Leu Glu Asn Gly Trp val Glu Ile Thr Ala Asn 
50 55 60 
Ser Ser Arg Leu val His Leu Asn Met Pro Glu Ser Glu Asn Tyr Arg 
65 70 75 80 
Arg val val val Asn Asn Leu Asp Lys Thr Ala val Asn Gly Asn Met 
85 90 95 
Ala Leu Asp Asp Thr His Ala Gln Ile val Thr Pro Trp ser Leu val 
100 105 110 
Asp Ala Asn Ala Trp Gly val Trp Phe Asn Pro Gly Asp Trp Gln Leu 
115 120 125 
Ile val Asn Thr Met Ser Glu Leu His Leu Val Ser Phe Glu Gln Glu 
130 135 140 
Ile Phe Asn val val Leu Lys Thr val Ser Glu Ser Ala Thr Gln Pro 
145 150 155 160 
Pro Thr Lys val Tyr Asn Asn Asp Leu Thr Ala Ser Leu Met val Ala 
165 170 175 
Leu Asp Ser Asn Asn Thr Met Pro Phe Thr Pro Ala Ala Met Arg Ser 
180 185 190 
Glu Thr Leu Gly Phe Tyr Pro Trp Lys Pro Thr Ile Pro Thr Pro Trp 
195 200 205 
Arg Tyr Tyr Phe Gln Trp Asp Arg Thr Leu Ile Pro Ser His Thr Gly 
210 215 220 
Thr Ser Gly Thr Pro Thr Asn~Tyr His Gly Thr Asp Pro Asp Asp 
225 230 ~ 235 240 
val Gln Phe Tyr Thr Ile Glu Asn Ser val Pro val His Leu Leu Arg 
245 250 255 
Thr Gly Asp Glu Phe Ala Thr Gly Thr Phe Phe Phe Asp Cys Lys Pro 
260 265 270 
cys Arg Leu Thr His Thr Trp Gln Thr Asn Arg Ala Leu Gly Leu Pro 
275 280 285 
Pro Phe Leu Asn ser Leu Pro Gln Ser Glu GlylA'solThr Asn Phe Gly 
290 295 "fflo 
Asp Ile Gly Ile Gln Gln Asp Lys Arg Arg Gly val Thr Gln Met Gly 
305 310 315 320 
Asn Thr Asn Tyr Ile Thr Glu Ala Thr Ile Met Arg Pro Ala Glu val 
325 330 335 
FIGURE 3A 
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Gly Tyr Ser Ala Pro Tyr Tyr Ser Phe Glu Ala Ser Thr Gln Gly Pro 
340 345 350 
Phe Lys Thr Pro Ile Ala Ala Gly Arg Gly Gly Ala Gln Thr Asp Glu 
355 360 365 
Asn Gln Ala Ala Asp Gly Asp Pro Arg Tyr Ala Phe Gly Arg Gln His 
370 375 380 
Gly Gln Lys Thr Thr Thr Thr Gly Glu Thr Pro Glu Arg Phe Thr Tyr 
385 390 395 400 
Ile Ala His Gln Asp Thr Gly Arg Tyr Pro Glu Gly Asp Trp Ile Gln 
405 410 415 
Asn Ile Asn Phe Asn Leu Pro Val xaa Asn Asp Asn Val Leu Leu Pro 
420 425 430 
Thr Asp Pro Ile Gly Gly LYS Thr Gly Ile Asn Tyr Thr Asn Ile Phe 
435 440 445 
Asn Thr Tyr Gly Pro Leu Thr Ala Leu Asn Asn val Pro Pro val Tyr 
450 455 460 
Pro Asn Gly Gln Ile Trp Asp Lys Glu Phe Asp Thr Asp Leu Lys Pro 
465 470 475 480 
Arg Leu His val Asn Ala Pro Phe val Cys Gln Asn ASn Cys Pro Gly 
485 490 495 
Gln Leu Phe val Lys val Ala Pro Asn Leu Thr Asn Glu Tyr Asp Pro 
500 505 510 
Asp Ala Ser Ala Asn Met Ser Arg Ile val Thr Tyr Ser Asp Phe Trp 
515 520 525 
Trp Lys Gly LYS Leu Val Phe Lys Ala Lys Leu Arg Ala Ser His Thr 
530 535 540 
Trp Asn Pro Ile Gln Gln Met ser Ile Asn val Asp Asn Gln Phe Asn 
545 550 555 560 
Tyr val Pro Ser Asn 
565 
Ile Gly Gly Met Lf Ile val Tyr Glu Lys Ser 5 0 575 
Gln Leu Ala Pro Arg Lys Leu Tyr His Thr Tyr Tyr val Phe Met Phe 
580 585 590 
Ile Thr Tyr Gln Pro Ser Thr 
595 
FIGURE 3A (con't) 
U.S. Patent May 27, 2014 Sheet 6 of 12 US 8,734,808 B2 
Met Ser Asp Gly Ala Val Gln Pro Asp GTy Gly Gln Pro Ala val Arg 
1 5 10 15 
Asn Glu Arg Ala Thr Gly Ser Gly Asn Gly Ser Gly Gly Gly Gly Gly 
20 25 30 
Gly Gly Ser Gly Gly val Gl y Ile Ser Thr Gly Thr Phe Asn Asn Gln 
35 40 45 
Thr Glu Phe LyS Phe Leu Glu Asn Gl y Trp val Glu Ile Thr Ala Asn 
50 55 60 
ser Ser Arg Leu val Hi S Leu Asn Met Pro Glu Ser Glu Asn Tyr Arg 
65 70 75 80 
Arg val val val Asn Asn Leu Asp Lys Thr Ala val Asn Gly Asn Met 
85 90 95 
Ala Leu Asp Asp Thr Hi S Ala Gln Ile Val Thr Pro Trp Ser Leu val 
100 105 110 
Asp Ala Asn Ala Trp Gly val Trp Phe Asn Pro Gly Asp Trp Gln Leu 
115 120 125 
Ile Val Asn Thr Met Ser Glu Leu His Leu val Ser Phe Glu Gln Glu 
130 135 140 
Ile Phe Asn val val Leu Lys Thr val Ser Glu ser Ala Thr Gln Pro 
145 150 155 160 
Pro Thr LYS val Tyr Asn Asn Asp Leu Thr Ala Ser Leu Met val Ala 
165 170 175 
Leu ASP Ser Asn Asn Thr Met Pro Phe Th r pro Al a Al a Met Arg Ser 
180 185 190 
Glu Thr Leu Gl y Phe Tyr Pro Trp Lys Pro Thr Ile Pro Thr Pro Trp 
195 200 205 
Arg Tyr Tyr Phe 
210 
Gln Trp Asp Arg Thr 
215 
Leu Ile Pro 
220 
Ser His Thr Gly 
Thr Ser Gly Thr Pro Thr Asn Thr Tyr His Gly Thr Asp Pro Asp Asp 
225 230 235 240 
val Gln Phe Tyr Thr Ile Glu Asn Ser Val Pro val His Leu Leu Arg 
245 250 255 
Thr Gly Asp Glu Phe Ala Thr Gly Thr Phe Phe Phe Asp cys Lys Pro 
260 265 270 
Cys Arg Leu Thr His Thr Trp Gln Thr Asn Arg Ala Leu Gly Leu Pro 
275 280 285 
Pro Phe Leu Asn Ser Leu Pro Gln Ser Glu Gly Asp Thr Asn Phe Gly 
290 295 300 
Asp Ile Gly Ile Gln Gln Asp Lys Arg Arg Gly val Thr Gln Met Gly 
305 310 315 320 
Asn Thr Asn Tyr Ile Thr Glu Ala Thr Ile Met Arg Pro Ala Glu val 
325 330 335 
FIGURE 3B 
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Gly Tyr Ser Ala Pro Tyr Tyr Ser Phe Gfo Ala Ser Thr Gln Gly Pro 
340 345 350 
Phe Lys Thr Pro Ile Ala Ala Gly Arg Gly Gly Ala Gln Thr Asp Glu 
355 360 365 
Asn Gln Ala Ala Asp Gly Asp Pro Arg Tyr Ala Phe Gly Arg Gln His 
370 375 380 
Gly Gln Lys Thr Thr Thr Thr Gly Glu Thr Pro Glu Arg Phe Thr Tyr 
385 390 395 400 
Ile Ala His Gln Asp Thr Gly Arg Tyr Pro Glu Gly Asp Trp Ile Gl n 
405 410 415 
Asn Ile Asn Phe Asn Leu Pro val xaa Asn Asp Asn val Leu Leu Pro 
420 425 430 
Thr Asp Pro Ile Gly Gly Lys Thr Gly Ile Asn Tyr Thr Asn Ile Phe 
435 440 445 
Asn Thr Tyr Gly Pro Leu Thr Ala Leu Asn Asn val Pro Pro Val Tyr 
450 455 460 
Pro Asn Gly Gln Ile Trp Asp Lys Glu Phe Asp Thr Asp Leu Lys Pro 
465 470 475 480 
Arg Leu His val Asn Ala Pro Phe val Cys Gln Asn Asn Cys Pro Gly 
485 490 495 
Gln Leu Phe val Lys val A la Pro Asn Leu Thr Asn Glu Tyr Asp Pro 
500 505 510 
Asp Ala Ser Ala Asn Met Ser Arg Ile val Thr Tyr Ser Asp Phe Trp 
515 520 525 
Trp Lys Gly Lys Leu val Phe Lys Ala Lys Leu Arg Ala Ser His Thr 
530 535 540 
Trp Asn Pro Ile Gln Gln Met Ser Ile Asn val Asp Asn Gln Phe Asn 
545 550 555 560 
Tyr Val Pro Ser Asn Ile Gly Gly Met Lys Ile val Tyr Glu Lys Ser 
565 570 575 
Gln Leu Ala Pro Arg Lys Leu Tyr 
580 
FIGURE 3B (con't) 
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5?:I VP genes 
Figure 4A-C 
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Fig.SB Recombinant virions 
---
FJ222821 :Canine paM'IArus 2c strain 56/ 
FJ222822:Canine paM'IArus 2b strain SAH 
FJ005259:Canine parw .... rus 2a strain 100 
F J005251: Canine parw .... rus 2c strain 239 
FJ222823:Canine parw .... rus 2b strain 29/ 
08080294RaccoonParwvirus VP-2 
FJ222824:Canine paM\Arus 2 strain 388/ 
,..._ ________________ U39014:Aleutian mink disease parw\Arus 
.__ _______________________ FJ440714:Feline panleukopenia virus isol 
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:::::tI;iG::)J Lys I Met I Lys I Ile I Val I Val I Ser I Ala I Asp I Asn I Val I Asn I Ala 
: :: :: :: :: : : :: :: :~::::::::::: 
:::)Si;;) Arg I Met I Asn I Ile I Val I Ile I Ser I Ala I Asp I Asn I Ile I Ser I Gly 
:::::::::::::::::::::::::::: 
:3Zi;;1jl Arg I Leu I Asn I Thr I Ala I Ile I Ser I Gly I Tyr I Asn I Val I Ser I Gly 
:::::::::::::::::::::::::::: 
CPV-2~) Arg I Leu I Asn I Thr I Ala I Ile I Ser I Gly I Tyr I Asp I Val I Ser I Gly 
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:5:l:i;}fll Arg I Leu I Asn I Thr I I Ile I Ala I Gly I Tyr I Glu I Val I Ser I Gly 
:::::::::::::::::::::::::::: 
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1 
ISOLATION OF A VIRUS RELATED TO 
CANINE PARVOVIRUS-2 FROM A RACCOON 
SEQUENCE LISTING 
2 
existing tools for cancer therapy, especially for geriatric dogs. 
The administration of oncolytic parvoviruses to kill cancer 
cells shows great promise as an effective cancer treatment 
(Rommelaere et al, Cytokine & Growth Factor Reviews 
This application includes as the Sequence Listing the com-
plete contents of the accompanying text file "PCT Sequence 
Listing_ST25.txt", created Oct. 14, 2010, containing 18,268 
bytes, hereby incorporated by reference. 
5 21:185-195, 2010; and U.S. Pat. No. 7,179,456 to Rom-
melaere et al, the complete contents of which are herein 
incorporated by reference) and might be applied to canines. 
However, the existence of pre-existing antibodies to parvovi-
ruses (e.g. as a result of vaccination) would render this 
DESCRIPTION 
BACKGROUND OF THE INVENTION 
1 o method ineffective, since the parvovirus would be neutralized 
by the existing antibodies. In addition, gene therapy in dogs is 
rarely undertaken at present but would be a promising method 
for treating several disorders, if suitable nucleic acid vectors 
are identified. 
1. Field of the Invention 
The invention generally relates to improved vaccines 
against canine parvovirus-like viruses. In particular, the 
invention provides vaccines suitable for puppies which are 
based on a novel parvovirus isolated from a raccoon. 
2. Background of the Invention 
Canine parvovirus (CPV) is primarily an enteric pathogen 
that infects dogs, especially young dogs. Parvovirus infection 
15 
20 
is characterized by acute diarrhea, fever and leukopenia in 
dogs and puppies more than 4 to 5 weeks old, and myocardial 
disease in younger puppies. The mortality rate from the dis- 25 
ease in unvaccinated dogs is very high. While vaccines 
against CPV are available, because CPV is a single-stranded 
DNA virus and has an extreme ability to mutate, the virus 
shows a remarkable ability to vary antigenically (Parrish and 
Kawaoka 2005) and thereby elude the immune protection 30 
afforded by vaccines. Thus, constant monitoring of the anti-
genic type and genotype of circulating viruses, and adjust-
ment of vaccine components accordingly, is necessary. 
Newborn puppies acquire immunities against diseases 
such as CPV infection by nursing from their mother, espe- 35 
cially during the first two days of life. A puppy that nurses 
takes in colostrum in the milk that is first produced and 
antibodies in the colostrum are passed to the puppy. For dogs 
and many other mammals as well, the immunity given by the 
colostrum loses its affect sometime around the fifth week of 40 
age. 
A particular challenge when vaccinating puppies is to 
administer vaccines according to a time frame that provides 
protection which overlaps the protection provided by mater-
nal antibodies and begins as maternal antibodies wane. Cur- 45 
rently, vaccine regimens for puppies typically begin at about 
6 weeks of age and boosters are given about every 3 weeks 
thereafter, e.g. at 9, 12 and 15 weeks. However, in order for 
this regimen to provide full protection, the first vaccine dose 
must immediately elicit a protective immune response. This is 50 
completely unrealistic due to the immaturity of the puppy's 
immune system and the time period required to mount an 
immune response. Full protection usually does not develop 
until the entire course of vaccinations is given. The age-based 
mortality due to CPV is depicted in FIG. 1, which shows that 55 
maximum mortality due to CPV occurs before vaccine pro-
tocols can be completed. 
The prior art has thus far failed to provide solutions to these 
problems. 
SUMMARY OF THE INVENTION 
The present invention is based on the discovery of novel 
parvoviruses (isolated from raccoons in the USA). Analyses 
of nucleotide and amino acid sequences showed that the 
viruses represent a unique variant of canine parvovirus type 2 
(CPV-2). This new CPV-2, denominated "AR08071304" (and 
referred to herein as raccoon parvovirus, "RPV", 
"08071304", and "Parvovirus-2 (Raccoon)" etc.) is useful as 
a component of vaccines against canine parvovirus. In par-
ticular, the variant is useful as a component of vaccines for 
very young dogs, e.g. puppies who are still nursing or who are 
in the process of being weaned, and thus solves the problems 
of how to provide adequate puppy vaccine protocols. This 
raccoon parvovirus will not be completely neutralized by 
existing canine parvovirus-2 antibodies in dogs. In addition, 
this raccoon parvovirus can be used as an oncolytic agent and 
as a vector ( carrier, vehicle) for gene therapy, due to the lack 
of neutralization by pre-existing antibodies in a recipient or 
host organism, e.g. a dog. 
The variant virus has close homology to the predominant 
CPV-2 viruses currently in circulation. Thus, administration 
of a vaccine containing the new variant is likely to result in an 
immune response that also affords protection against known 
circulating CPV-2 viruses. However, there are some antigenic 
differences between the new isolate and known CPV-2 
viruses to which a mother dog is likely to have been exposed 
( e.g. via a vaccine preparation or prior CPV exposure). In 
particular, amino acid residue 232 of the variant capsid pro-
tein, VP-2 is Thr ( encoded by ACA) and amino acid residue 
300 is Asp ( encoded by GAT). These differences in sequence 
are sufficient to result in a unique immunoreactive profile for 
the variant. Therefore, maternal antibodies passed to a puppy 
(e.g. from a previously vaccinated/exposed mother) are not 
likely to completely inactivate the new virus when it is admin-
istered to a puppy as a vaccine. As a result, an immune 
response by the puppy's own immune system will be elicited 
upon exposure to the RPV of the present invention via vacci-
nation, and the immune response is likely to be broadly pro-
tective against currently circulating CPV's in general. More-
over, this raccoon parvovirus appears to be a natural chimera 
of carnivore parvoviruses. Although the nucleotide sequence 
encoding the RPVVP-2 protein has the highest total homol-
ogy score (3309) with canine parvovirus-2a (CPV-15), it also 
has high homology with feline panleukopaenia, previously 
isolated raccoon parvoviruses, and mink enteritis virus. This 
type of chimeric sequence has not been observed previously 
A simple answer might be to begin the vaccination pro-
gram even earlier, e.g. at 2-3 weeks. However, this would be 
futile because, for puppies whose mothers have been vacci- 60 
nated with or otherwise exposed to a viral strain with the same 
antigenic determinants, maternal antibodies passed to the 
puppy would neutralize viruses in the vaccine, thereby pre-
venting the puppy's own immune system from responding to 
the virus. 65 in canine or feline parvovirus sequences, although similar 
parvoviruses now appear to be circulating in raccoon popu-
lations in the USA (see Examples section below). This RPV 
Another challenge in veterinary medicine is the treatment 
of cancer, e.g., in dogs. There are many limitations in the 
US 8,734,808 B2 
3 
will provide broad immune protection in several carnivore 
species and is thus suitable for use as a broad spectrum par-
vovirus vaccine. Under rare, unusual circumstances, a dog or 
cat might succumb to infection with a heterologus live, non-
attenuated carnivore parvovirus; however, the benefits of 5 
using the RPV of the invention as described herein far out-
weigh this minimal risk. 
4 
ments, the attenuated parvovirus virion is present in a solid 
carrier suitable for supralingual dissolution. In yet other 
embodiments, the immununogenic composition is suitable 
for subcutaneous administration. 
The invention also provides a method of eliciting an 
immune response in an animal against parvovirus infection. 
The method comprises the step of administering to the animal 
an immunogenic composition comprising a nucleic acid com-
prising the nucleotide sequence SEQ ID NO: 1, or a portion of 
Although the present invention is not premised on any 
evolutionary model or theory, one interesting interpretation 
of the genetic data disclosed herein is that the RPV of the 
present invention may represent the ancestor of present-day 
canine and feline parvoviruses. There is an ongoing debate in 
virology community concerning the origin of parvovirus-2 of 
dogs, and the RPV of the invention would, within the confines 
of this theory, be a "living fossil" of canine parvovirus-2. In 
any case, the RPV described herein encodes a unique VP-2 
protein, which comprises a mosaic of feline and canine par-
vovirus amino acid sequences. Thus the RPV of the present 
invention is a candidate for being the "ancestor" of both feline 
and canine parvoviruses, i.e., these newer carnivore parvovi-
ruses having originated from this RPV. Alternatively, the RPV 
of the present invention may represent a chimeric intermedi-
10 SEQ ID NO: 1; wherein said portion of SEQ ID NO: 1 
encodes an antigenic region of a VP-2 protein comprising 
amino acid residue 232 of SEQ ID NO: 3, amino acid residue 
300 of SEQ ID NO: 3 or both amino acid residue 232 and 
amino acid residue 300 of SEQ ID NO: 3. In some embodi-
15 ments, the nucleic acid is present in a killed or attenuated 
parvovirus virion or low passage RPV in a killed or attenuated 
parvovirus virion. In some embodiments, the killed parvovi-
rus virion comprises the characteristics of Parvovirus-2(Rac-
coon) having the ATCC NO. PTA-11400. In some embodi-
20 ments, the attenuated parvovirus virion is present in a solid 
carrier suitable for supralingual dissolution, and in some 
embodiments, the animal is a puppy. In other embodiments, 
the immununogenic composition is suitable for subcutaneous ate at the "intersection" of parvovirus evolution. In any case, 
this RPV provides an avenue for cross-immunization against 
heterologous parvoviruses that is otherwise not presently 25 
available with any of the more species-specialized canine and 
feline parvoviruses. Moreover, the RPV of the invention is 
weakly agglutinating for porcine erythrocytes (transferrin); 
does not share some critical epitopes ( e.g., amino acid residue 
300 of the VP-2 protein sequence); and grows poorly in feline 
kidney cell lines (see Examples below). Taken together, these 
indications are consistent with a virus that either predates or 
administration. 
The invention further provides a substantially purified par-
vovirus VP-2 protein that has a threonine residue at amino 
acid position 232 and an aspartic acid residue at amino acid 
position 300; or an antigenic fragment thereof, wherein said 
antigenic fragment comprises at least a portion of said VP-2 
is an early intermediate in the evolutionary cascade of canine 
and feline parvoviruses. 
30 protein that has: a threonine residue at amino acid position 
232; or an aspartic acid residue at amino acid position 300; or 
both a threonine residue at amino acid position 232 and an 
aspartic acid residue at amino acid position 300. In some 
embodiments, the substantially purified parvovirus VP-2 pro-
The invention provides a parvovirus comprising the char-
acteristics of the Parvovirus-2 (Raccoon) ofATCC NO. PTA-
11400, deposited at the American Type Culture Collection, 
10801 University Blvd, Manassas, Va., on Oct. 7, 2010. 
35 tein comprises amino acid sequence SEQ ID NO: 3. 
The invention also provides expression vectors comprising 
a nucleotide sequence encoding the amino acid sequence of 
SEQ ID NO: 3, or a portion of SEQ ID NO: 3; wherein said 
portion of SEQ ID NO: 3 is an antigenic region of a VP-2 
40 protein comprising amino acid residue 232 of SEQ ID NO: 3, 
amino acid residue 300 of SEQ ID NO: 3 or both amino acid 
residue 232 and amino acid residue 300 of SEQ ID NO: 3. In 
some embodiments, the expression vector is a recombinant 
viral expression vector. In other embodiments, the recombi-
In addition, the invention provides vaccines comprising a 
parvovirus comprising the characteristics of the Parvovirus-2 
(Raccoon) having the ATCC NO. PTA-11400. In one embodi-
ment, the vaccine further comprises one or more antigenic 
components selected from the group consisting of canine 
distemper virus (CDV), canine adenovirus type 2, canine 
parainfluenza virus, canine corona virus, canine herpes virus, 
canine rotavirus, one or more Leptospira serovars, and a 
canine parvovirus-2 in which the amino acid at position 232 
ofVP-2 protein is not Thr and the amino acid at position 300 
ofVP-2 protein is not Asp. In some embodiments, the one or 
more Leptospira serovars is selected from the group consist- 50 
ing of Leptospira interrogans serovar canicolar, Leptospira 
interrogans serovar icterohaemorrhagiae, Leptospira inter-
rogans serovar Pomona, and Leptospira kirschneri serovar 
grippotyphosa. 
45 nant viral expression vector is a canarypox viral expression 
The invention also provides isolated nucleic acids compris- 55 
ing the nucleotide sequence SEQ ID NO: 1, or a portion of 
SEQ ID NO: 1; wherein the portion of SEQ ID NO: 1 encodes 
an antigenic region of a VP-2 protein comprising amino acid 
residue 232 of SEQ ID NO: 3, amino acid residue 300 of SEQ 
ID NO: 3 or both amino acid residue 232 and amino acid 60 
residue 300 of SEQ ID NO: 3. In other embodiments, the 
invention provides immununogenic compositions compris-
ing this nucleic acid, wherein the nucleic acid is present in a 
killed or attenuated parvovirus virion or low passage raccoon 
parvovirus (RPV). In some embodiments, the killed parvovi- 65 
rus virion comprises the characteristics of Parvovirus-2 (Rac-
coon) having the ATCC NO. PTA-11400. In other embodi-
vector. 
The invention also provides methods of killing tumor cells 
in a mammal. The methods comprise the step of administer-
ing to the mammal a composition comprising a parvovirus 
comprising the characteristics of the Parvovirus-2 (Raccoon) 
of ATCC NO. PTA-11400, in a quantity sufficient to infect 
and kill said tumor cells in the mammal. In some embodi-
ments, the mammal is a dog that is seropositive for canine 
parvovirus-2. In other embodiments, the method is carried out 
by a route of administration selected from the group consist-
ing of intravenous and intratumoral. In yet other embodi-
ments, the parvovirus is a low passage parvovirus. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Distribution of CPV-2 genotypes and number of 
fatal cases of CPV infection with respect to age of dog. 
FIGS. 2A and B. Nucleic acid sequences encoding the 
VP-2 proteins of the new AR08071304 CPV-2 variant.A, the 
longer version of the nucleotide sequence (SEQ ID NO: 1) 
which encodes a 599 amino acid protein. The internal stop 
codon located at nucleotides 1753-1755 is shown in bold and 
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underlined. B, the shorter version of the nucleotide sequence 
(SEQ ID NO: 2) which encodes a 584 amino acid protein. In 
both A and B, the nucleotides encoding Thr at position 232 
(nts 694-696) and the nucleotides encoding Asp at position 
300 (nts 898-900) are underlined. 
FIGS. 3A and B. Amino acid sequence of the VP-2 protein 
of the new AR08071304 CPV-2 variant. A. (SEQ ID NO: 3), 
6 
different forms. One form, shown in FIG. 3A (SEQ ID NO 3) 
results from readthrough ("leakiness") of the stop codon and 
is thus longer (599 amino acids) than the second form, which 
is shown in FIG. 3B, and which terminates at the stop codon. 
5 The second form of the protein contains only 584 amino acids 
(SEQ ID NO: 4). In the first, longer form ofVP-2 the stop 
codon is not translated but is "skipped", resulting in the 599 
amino acid protein. The term "VP-2" protein as used herein is the longer version of the protein when all 599 encoded 
amino acids are translated; B, (SEQ ID NO: 4), is the shorter 
version of the protein when termination occurs at the stop 10 
condon. Amino acid positions 232 and 300, which are Thr and 
Asp, respectively in both proteins, are boxed. 
encompasses both the first longer form ofVP-2 and the sec-
ond, shorter form ofVP-2, and both forms of the protein may 
be used in the practice of the invention. These two forms of 
the protein can be detected using Western blots. In addition, 
both nucleic acid sequences (SEQ ID NOS: 1 and 2) may be 
FIG. 4A-C. Schematics of: A, raccoon parvovirus (RPV) 
DNA; B, RPV open reading frame arrangement; C, binding of 
RPV to eukaryotic cells. 
FIGS. SA and B. A, Schematic of raccoon parvovirus bind-
ing to cell surface transferrin receptor (TFR); B, schematic of 
general strategy for preparing autonomous parvovirus vec-
tors. 
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used in the practice of the present invention, e.g. either or both 
of the sequences may be used in a vaccine preparation, in a 
vector, etc. In some embodiments, the amino acid sequence of 
SEQ ID NO: 3 is encoded by the nucleotide sequence of SEQ 
ID NO: 1. In other embodiments, the amino acid sequence of 
FIG. 6. Relatedness of the newly isolated raccoon parvovi- 20 
rus to other similar viruses. 
SEQ ID NO: 4 is encoded by SEQ ID NO: 2. In yet other 
embodiments of the invention, SEQ ID NO: 1 may be modi-
fied by elimination ( deletion) of the stop codon ( e.g. by 
genetic engineering) so that the amino acid sequence of SEQ 
ID NO: 3 is translated therefrom. 
FIG. 7. Amino acids at critical epitopes in VP-2 protein of 
the newly isolated raccoon parvovirus. 
FIG. 8. Phylogenetic tree comparing the VP-2 protein of 
the newly isolated raccoon parvovirus with those of other 25 This novel RPV also serves as a model for proper boosting 
carnivore parvoviruses. CPV=canine parvovirus; 
RPV=raccoon parvovirus; FPV=feline parvovirus; 
PV=parvovirus; MEV=mink enteritis virus; FPL=feline pan-
leukopenia virus; Aleu=Aleutian mink disease parvovirus; 
MVC=minute virus of canines. 
DETAILED DESCRIPTION 
of other animal and human infections. For example in human 
influenza (HlNl) based on available information, vaccine 
response varies depending on the existence of pre-existing 
antibodies. If a person has pre existing antibodies, the titer 
30 does not go up but the affinity of the antibodies does increase. 
If a person does not have a pre-existing titer, then the person 
does respond with development of neutralizing protective 
immunity. 
The invention provides vaccine and virotherapy prepara-
tions comprising attenuated forms of a novel parvovirus vari- 35 
ant isolated from an infected raccoon. While the vaccine 
The new isolate was deposited at the American Type Cul-
ture Collection in Manassas, Va., on Oct. 7, 2010, as Parvovi-
rus-2 (Raccoon), on behalf of Oklahoma State University, 
(acknowledgement from the ATCC of receipt was received on 
Oct. 12, 2010), andassignedATCC Deposit No. PTA-11400. 
The invention also provides an isolated parvovirus compris-
preparations are suitable for administration to a wide variety 
of carnivores ( e.g. dogs, cats, mink, raccoon, members of 
canidae, procyonidea, mustelidae, and viveridae etc.), they 
are particularly useful for administration to very young dogs 
(puppies). This is because the new variant differs enough 
from CPV variants that are used in current vaccines so as to 
make it unlikely that maternal antibodies ( developed in 
response to vaccine administration and passed to the puppies 
while nursing) would recognize and inactivate the virus. 
Similarly, for other applications in dogs, including adult dogs 
(e.g. as a treatment for cancer and as a gene therapy vector) 
the RPV will bypass the preexisting antibodies from previous 
vaccinations, and hence evade immediate immune clearance. 
Notably, in the VP-2 protein of the raccoon isolate amino acid 
residue 232 is Thr ( encoded by ACA) and residue 300 is Asp 
( encoded by GAT). These two amino acid residues in the RPV 
are thus distinct from those of the VP-2 proteins of all other 
known CPV isolates and may be responsible for the unique 
properties (e.g. antibody reactivity, see Examples below) of 
this RPV. Due to attenuation, the virus will not cause disease 
in vaccine recipients. On the other hand, the new isolate is 
similar enough to viruses which are currently in circulation 
(e.g. the amino acid sequence identity is -99% for the VP-2 
protein) that is it likely that administration of the virus to a 
young animal would result in the production of antibodies, at 
least some of which would cross react with known circulating 
viruses, and thus afford protection against those viruses to the 
vaccinated young animal. 
40 ing the characteristics of ATCC Deposit No. PTA-11400, and 
progeny thereof. The invention further encompasses killed or 
attenuated parvoviruses comprising the characteristics of 
ATCC Deposit No. PTA-11400, deposited on Oct. 7, 2010 
and progeny of the attenuated parvoviruses, as well as vac-
45 cines and immunogenic compositions comprising the same. 
The invention also provides other RPV' s isolated in Illinois 
and propagated in CRFK. (10071199-A and 10071199-C), 
the partial sequences of which are given in the Examples 
section. Thus, the invention also encompasses raccoon par-
50 voviruses that are circulating in the USA ( e.g. inArkansas and 
Illinois), the common feature of which is that they do not react 
with the canine parvovirus monoclonal antibody (MoAb) 
3B 10, the MoAb that is most commonly used for diagnostics. 
3B10 is specific for amino acid position 300 ofVP-2, which 
55 is usually glycine. Thus, these RPV have a mutation at amino 
acid 300 ofVP-2 that is included within the foot-print of this 
MoAb and prevents it from recognizing the proteins. Other-
wise, these viruses have about 98% homology with the VP-2 
of other carnivore parvoviruses-2. However, it is well-estab-
60 lished that even a small number of mutations at critical loca-
tions can have a large impact on the properties of a virus ( e.g. 
see Que al, 2005, where mutations in two critical amino acid 
residues of coronavirus spike protein, which altered its tro-
pism, are described.) 
A nucleic acid sequence described herein (SEQ ID NO: 1) 65 
contains an internal stop codon at nucleotides 1753-1755 (see 
FIG. 2A). The VP-2 protein translated therefrom thus has two 
Phylogenetic studies of this virus ( e.g. see Examples 1 and 
5) have shown that this RPV [Parvovirus-2 (Raccoon)] is 
closely related to, and in fact may be, a variant of canine 
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CPV-2. As such, domestic adult dogs may also be susceptible 
to the virus and would likely benefit from receiving vaccines 
which include this variant. 
Transmission of the newly isolated parvovirus from rac-
coons to domestic pets such as dogs, and also to other wildlife 
is likely to occur due to raccoon behavioral characteristics. 
For example, raccoons are highly intelligent and very quick to 
adapt to new food sources. They are omnivorous, eating a 
wide rage of plants and animals, depending upon season and 
availability. Due to their ready integration into and adaption 
to urban areas, raccoons commonly interact with and make 
close contact with domestic dogs and cats. Raccoons have 
excellent prehensile abilities and readily learn, e.g. to open 
containers, to locate and open stored animal food, etc. Due to 
this behavior, they are potentially able to transmit parvovirus 
to domestic carnivores. Raccoons also interact with other 
wildlife such as skunks and there is thus a potential for inter-
species interaction and transmission of parvoviruses as well. 
Thus, adult dogs and other domestic pets would thus benefit 
from receiving vaccines which included the raccoon virus 
described herein, even if they have previously been vacci-
nated with another parvovirus vaccine; and other species, 
whether domesticated or not, would also benefit from receiv-
ing such vaccines. The benefits could be two-fold: 1) vacci-
nation would provide immunity to infection with this particu-
lar CPV; and 2) this CPV is similar enough to other 
parvoviruses ( e.g. about 99% homologous to other carnivore 
parvoviruses) that is would likely also elicit and boost at least 
some immunity against them. 
In some embodiments, the vaccines and immunogenic 
compositions of the invention are monovalent in nature, i.e. 
that contain a single agent which is the parvovirus isolate 
described herein ( e.g. with the characteristics of Parvovirus-2 
(Raccoon), ATCC Deposit No. PTA-11400 deposited on Oct. 
7, 2010), or an attenuated or killed form of the isolate 
described herein, or progeny of any of these. In other embodi-
ments, the vaccines and immunogenic compositions are poly-
valent, i.e. they contain a plurality of antigenic agents, one of 
which is the isolate of the present invention. Exemplary addi-
tional components of the multivalent compositions include 
but are not limited to one or more of a canine distemper 
viruses (CDV), canine adenovirus type 2, canine parainflu-
enza virus, canine corona virus, canine herpes virus, canine 
rotavirus, one or more Leptospira serovars, and a canine 
parvovirus-2 which differs in sequence of the VP-2 gene, i.e. 
in which the amino acid at position 232 of the VP-2 protein is 
not Thr and/or the amino acid at position 300 of the VP-2 
protein is not Asp; or in which the codon encoding Thr at 
amino acid position 232 of the VP-2 protein is not ACA, 
and/or the codon encoding Asp at amino acid position 300 of 
the VP-2 is not GAT. Exemplary CDVs include but are not 
limited to those described in U.S. patent application Ser. No. 
12/696,983 (Kapil), published as US2010/0196420, the com-
plete contents of which are hereby incorporated by reference. 
Exemplary Leptospira serovars include but are not limited to 
Leptospira interrogans serovar canicolar, Leptospira inter-
rogans serovar icterohaemorrhagiae, Leptospira interrogans 
serovar pomona, and Leptospira kirschneri serovar grippoty-
phosa. Further, the isolate of the invention may be combined 
with a plurality of different antigens e.g. those of known 
multivalent vaccines such as Galaxy® DA2PPV, or Nobivac 
DA2PPv+L4, etc. 
In a particular embodiment, the recipient of a vaccine of the 
invention is a juvenile animal ( e.g. a puppy) and the mode of 
administration is via a "puppy lollipop". Puppy lollipops for 
use in administering vaccine compositions to young dogs ( or 
the young of other species) are described in detail in co-
8 
pending PCT patent application no. PCT/US2010/042142 to 
Kapil et al., filed Jul. 15, 2010, the complete contents of 
which is hereby incorporated by reference. Briefly, a puppy 
lollipop or similar device is used to deliver the vaccine to the 
5 dorsal side of the tongue, i.e. supralingually. In particular, the 
vaccine preparation is administered in a manner that delivers 
the vaccine at or near the basal cells of the tongue. Basal cells 
are infected by the attenuated parvovirus in the vaccine, and 
an antigen depot (e.g. a reservoir of virus) is established 
10 which gradually, over time and from a very young age, 
releases attenuated parvovirus within the puppy. This method 
takes advantage of the fact that the tongue is relatively immu-
nologically privileged ( devoid ofimmune response). The vac-
15 cine may, for example, be included in a hand-held "puppy 
lollipop" that is administered supralingually by a caregiver, 
e.g. by holding a stick, string or other delivery vehicle 
attached to a solid vaccine formulation which is placed in the 
puppy's mouth. The solid formulation includes a solid, inert 
20 carrier; with the parvovirus dispersed or distributed through-
out the solid carrier, and the innate suckling response by the 
puppy gradually dissolves the carrier and the parvovirus is 
released to the tongue. 
In one embodiment, the invention comprises nucleic acids 
25 with a nucleotide sequence encoding the VP-2 protein of the 
RPV, such as that which is set forth in SEQ ID NO: 1, or 
alternatively SEQ ID NO: 2 (see FIGS. 2A and B), or portions 
of that nucleotide sequence that encode antigenic regions or 
epitopes sufficient to elicit an immune response to the RPV in 
30 a vaccine recipient, and vaccines comprising the same. In 
particular, such nucleic acid sequences will include one or 
both of the codons which encode positions 232 and 300 of the 
VP-2 protein. Those codons are ACA and GAT, respectively, 
encoding Thr and Asp, respectively. In another embodiment, 
35 the invention comprises nucleic acids with a nucleotide 
sequence encoding a VP-2 protein comprising the amino acid 
sequence as set forth in SEQ ID NO: 3 ( or alternatively, SEQ 
ID NO: 4, which is encompassed by SEQ ID NO: 3, see FIGS. 
3A and B) or portions of the amino acid sequence set forth in 
40 SEQ ID NO: 3 which include antigenic regions or epitopes 
sufficient to elicit an immune response to the antigenic 
regions or epitopes in a vaccine recipient, and vaccines com-
prising the same. In particular, such proteins or portions 
thereof will include one or both of amino acid residues 232 
45 and 300 of the RPV VP-2 protein, which are Thr and Asp, 
respectively. Variants and/or derivatives of such sequences, as 
described herein, and vaccine preparations which include the 
variants and/or derivatives, are also encompassed by the 
invention. For example, those of skill in the art will recognize 
50 that, due to the redundancy of the genetic code, sequences 
other than SEQ ID NO: 1 may be utilized to encode the amino 
acid sequence set forth in SEQ ID NO: 3. In addition, while 
the nucleotide sequence set forth in SEQ ID NO: 1 represents 
single-strand (ss)DNA, the invention also includes corre-
55 sponding double-strand ( ds) DNA, complementary DNA, 
and RNA of any form ( e.g. mRNA, RNA/DNA hybrids, etc.) 
that is based on, derived from or that complements these 
sequences. Such sequences may be either sense or antisense 
sequences. Further, sequences which display at least about 
60 50% homology, preferably about 60%, more preferably about 
70, 80, or90%homology, or even about 95, 96, 97, 98 or99% 
or greater homology to SEQ ID NO: 1 are also contemplated 
for use in the vaccines, so long as the sequence encodes one or 
both of amino acid residues 232 and 300 as Thr and Asp, 
65 respectively. Such sequences may differ, for example, by 
containing alternate codons that encode the same amino acid 
at one or more positions. 
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In addition, portions of these sequences which encode 
antigenic regions or epitopes oftheAR08071304 VP-2 pro-
tein are also contemplated. In particular, nucleotide 
sequences encompassing codons which encode one or both of 
amino acid residues 232 and 300 as Thr andAsp, respectively, 
are contemplated. In one embodiment, the codon encoding 
amino acid residue 23 2 as Thr is ACA and the codon encoding 
residue 300 as Asp is GAT. In addition, sequences which 
encode amino acid sequences displaying 70%, or more pref-
erably about 80, 90, or 95% or even greater identity ( e.g. 96, 
97, 98 or 99% identity) to SEQ ID NO: 3, so long as the 
sequence encodes one or both of amino acid residues 232 and 
300 as Thr and Asp, respectively, or variants and/or deriva-
tives thereof, including shorter antigenic regions or epitopes, 
are also included. Such variants and/or derivatives of SEQ ID 
NO: 3 and/or antigenic regions or epitopes thereof may vary, 
for example, by containing conservative or non-conservative 
amino acid substitutions, or deletions ( especially amino or 
carboxy terminal deletions), or various insertions, etc., so 
long as the resulting protein/peptide is antigenic and elicits an 
immune response in a vaccine recipient. Such antigenic 
regions or epitopes are preferably at least about 10 amino 
acids in length and encompass one or more of amino acid 
positions 232 and 300, with reference to amino acid residue 
numbering in the VP-2 protein as depicted in FIG. 3, which 
are Thr and Asp respectively. An antigenic region may, how-
ever, encompass the entire AR08071304 VP-2 gene/protein. 
Further, nucleic acid sequences which hybridize to 
sequences disclosed herein ( or to portions of those 
sequences) under stringent conditions ( especially conditions 
of high stringency) are also contemplated, so long as the 
sequence encodes one or both of amino acid residues 232 and 
300 as Thr and Asp, respectively. Stringent conditions refer to 
hybridization conditions which allow a nucleic acid sequence 
to hybridize to a particular sequence. In general, high strin-
gent conditions refer to the hybridization conditions which 
allow a nucleic acid sequence of at least 50 nucleotides and 
preferably about 200 or more nucleotides to hybridize to a 
particular sequence at about 65° C. in a solution comprising 
about 1 M salt, preferably 6xSSC or any other solution having 
a comparable ionic strength, and washing at 65° C. in a 
solution comprising about 0.1 M salt, or less, preferably 
0.2xSSC or any other solution having a comparable ionic 
strength. These conditions allow the detection of sequences 
having about 90% or more sequence identity. In general, 
lower stringent conditions refer to the hybridization condi-
tions which allow a nucleic acid sequence of at least 50 
nucleotides and preferably about 200 or more nucleotides to 
hybridize to a particular sequence at about 45° C. in a solution 
comprising about 1 M salt, preferably 6xSSC or any other 
solution having a comparable ionic strength, and washing at 
room temperature in a solution comprising about 1 M salt, 
preferably 6xSSC or any other solution having a comparable 
ionic strength. These conditions allow the detection of 
sequences having up to 50% sequence identity. The person 
skilled in the art will be able to modify these hybridization 
conditions in order to identify sequences varying in identity 
between 50% and 90%. 
The invention thus also provides various types of recom-
binant and/or expression vectors that contain and express the 
nucleic acid sequences disclosed herein ( or portions thereof 
that encode antigenic peptides and/or polypeptides). Such 
vectors may be used in vaccine preparations, or may serve 
other purposes such as for manipulation of the disclosed 
sequence in a laboratory setting. Examples of such vectors 
and expression systems include but are not limited to: various 
bacterial ( e.g. Escherichia coli) or pro biotic-based ( e.g. Lac-
10 
tobacillus) expression vectors; various recombinant viral 
vectors such as adenoviral vectors, baculovirus, canarypox 
vectors, etc.; Pichia, and yeast expression systems, etc. Such 
recombinant vectors and expression systems may be utilized, 
5 for example, in vaccine preparations, or, alternatively, for 
other purposes such as for laboratory manipulation of the 
sequences, or for research or diagnostic purposes. 
The invention also contemplates chimeric proteins and 
genes encoding the same, such proteins comprising the VP-2 
10 protein of the RPV of the invention, or antigenic regions or 
epitopes thereof. In certain embodiments, such epitopes are 
of a size in the range of from at least about 5 to about 20 or 
more amino acids. Such chimeric proteins (or nucleic acid 
sequences that encode them) may include other useful amino 
15 acid sequences, such as adjuvants, other proteins that are 
vaccine targets e.g. from other organisms that cause disease in 
carnivores, especially canids, etc. Nucleic acids encoding 
such proteins may include linker or spacer sequences e.g. 
between antigenic regions or epitopes. Also included are 
20 recombinant and/or expression vectors that encode and/or 
expresse such chimeric (or fusion) proteins. 
Several methods of making vaccines suitable for vaccina-
tion against parvovirus are known in the art. See, for example, 
U.S. Pat. Nos. 4,193,990 and 4,193,991 to Appel et al., U.S. 
25 Pat. No. 4,303,645 to Carmichael et al., U.S. Pat. No. 4,971, 
793 to Wood et al.; U.S. Pat. No. 5,882,652 to Valdes et al., 
and U.S. Pat. No. 5,885,585 to Parrish et al., each of which 
offers variations of suitable vaccine-formulating strategies. 
The complete contents of each of these patents are hereby 
30 incorporated by reference. Generally, to manufacture a vac-
cine, a viral vector containing the described nucleic acid 
sequences ( e.g. ssDNA naturally occurring within a virus, or 
ssDNA or other equivalent form genetically engineered into a 
non-native viral vector (e.g. dsDNA, ss or dsRNA, RNA-
35 DNA hybrids, etc.) will be employed. Examples include RPV 
(or other) viruses that are "killed", inactivated or otherwise 
attenuated so as to not cause severe disease symptoms in the 
animal to which it is administered, together with a suitable 
physiological carrier. Preferably, no disease symptoms will 
40 occur as a result of administration. However, those of skill in 
the art will recognize that many effective vaccine composi-
tions cause some discomfort or relatively minor distress upon 
or after administration. However, the benefits of being pro-
tected against full-blown disease far outweigh this possibility. 
45 As an alternative, a heterotypic virus that does not naturally 
infect or that does not normally cause disease in the animal 
being vaccinated may be utilized. Examples of ways of inac-
tivating the antigens of the present invention ( e.g., the RPV of 
the present invention) include, but are not limited to, heat, 
50 formaldehyde, formalin, biethylene amine, radiation, and 
beta-propiolactone treatment. 
Other suitable vaccine components, e.g. pharmacologi-
cally acceptable carriers, are well-known to those of skill in 
the art, as is the preparation of such compositions for use as 
55 vaccines. Typically, such compositions are prepared either as 
liquid solutions or suspensions, however solid forms such as 
tablets, pills, powders and the like are also contemplated. 
Solid forms suitable for solution in, or suspension in, liquids 
prior to administration, or for dissolution in the mouth, may 
60 also be prepared. The preparation may also be emulsified. The 
active ingredients may be mixed with excipients which are 
pharmaceutically acceptable and compatible with the active 
ingredients. Suitable excipients are, for example, water, 
saline, dextrose, glycerol, ethanol and the like, or combina-
65 tions thereof. In addition, the composition may contain minor 
amounts of auxiliary substances such as wetting or emulsify-
ing agents, pH buffering agents, and the like. If it is desired to 
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tionally similar amino acids in corresponding positions ( e.g. 
Asp and Glu, which both possess a side chain that is usually 
negatively charged at neutral pH, and thus may function simi-
larly). Thus, similarity between polypeptide sequences indi-
administer an oral form of the composition, various thicken-
ers, flavorings, diluents, emulsifiers, dispersing aids or bind-
ers and the like may be added. The composition of the present 
invention may contain any such additional ingredients so as to 
provide the composition in a form suitable for administration. 
The final amount of the translatable nucleic acid in the for-
mulations may vary. However, in general, the amount will be 
from about 1-99%. The compositions may further comprise 
5 cates functional similarity, in addition to sequence similarity. 
The sequences encompassed by the invention may differ from 
those which are explicitly disclosed, for example, by having 
conservative amino acid substitutions, as are understood by 
those of skill in the art ( e.g. positively charged amino acids an adjuvant, suitable examples of which include but are not 
limited to Seppic, Qui! A, Alhydrogel, etc. 
Generally, for administration as a vaccine, a nucleic acid 
will be included in a virus or virion particle and the entire 
particle will be a vaccine component. As will be understood 
by those of skill in the art, when the vaccine contains virions 
(such as the RPV of the present invention) they will be inac-
tivated (killed) or attenuated, i.e. obtained after several pas-
sages of the virus in cell culture so that particles do not cause 
symptoms of disease, or cause only mild, non-life threatening 
symptoms. Those of skill in the art will also recognize that 
other methods of attenuating viruses exist, and any of these 
may be used in the practice of the present invention to develop 
a suitable form of the variant virus disclosed herein. For 
example, various mutations that interfere with virus toxicity, 
ability to reproduce, etc. may be introduced. 
10 may be substituted for one another, negatively charged amino 
acids may be substituted for one another, aliphatic amino 
acids may be substituted for one another, etc.), so long as the 
amino acid sequence retains the ability to elicit an effective, 
suitable immune response upon administration to a vaccine 
15 recipient. Further, the invention also encompasses amino acid 
sequences of antigenic regions or epitopes that are short con-
tiguous sequences within SEQ ID NO: 3 (i.e. truncated or 
partial sequences which represent a portion of SEQ ID NO: 3) 
but which retain the ability to elicit an effective, suitable 
20 immune response against the development of symptoms of 
canine parvovirus infection in a vaccine recipient. Such anti-
genic regions are generally in the range of about 5-10 amino 
acids in length, but may be about 15, 20, 25, 30, 35, 40, 45 or 
even about 50 amino acids or more in length, and will gener-
Alternatively, the nucleotide sequence presented in SEQ 
ID NO: 1 ( or segments thereof that encode antigenic regions 
25 ally encompass one or both of amino acid residues 232 and 
300. 
or epitopes as described herein, for example SEQ ID NO: 2)) 
may be delivered in a heterologous vector such as a different 
virus (e.g. a virus that does not cause disease in the vaccine 
recipient species), or another type of construct that is 30 
designed to result in expression of the encoded protein in the 
vaccine recipient, without causing symptoms of disease. 
Examples of such viruses include but are not limited to feline 
panleukopenia virus (FPV), various herpesviruses, non-
pathogenic "orphan viruses", enteric viruses such as enterovi- 35 
rus, etc. Other forms of the vaccine are also contemplated. For 
example, "empty" virion particle vaccines (without nucleic 
acid) are also contemplated, as are vaccines comprising pro-
teins that are not assembled into a capsid. The RPV s of the 
invention may also be substantially or partially purified and/ 40 
or concentrated by panning e.g. with transferrin coated beads 
in a colunm, in dishes, etc. 
The RPVs of the invention may be safely administered at 
very high titers. For example, a usual dose of CPV-2 in a 
vaccine is about 10,000 virus particles per injection. The 45 
amount administered when RPV is used ranges from about 
10,000 particles per injection to about 100,000 particles per 
injection, or even higher, e.g. from about 100,000 up to about 
1,000,000 particles per injection. 
Alternatively, the vaccine preparation may include a VP-2 50 
protein (polypeptide, peptide, etc.) sequence as set forth in 
SEQ ID NO: 3, or in SEQ ID MO: 4, or antigenic regions or 
epitopes thereof. Further, sequences which display at least 
about 50% identity, preferably about 60%, more preferably 
about 70, 80, or 90% identity or similarity, or even about 95, 55 
96, 97, 98 or 99% or greater identity or similarity to SEQ ID 
NO: 3 or SEQ ID NO: 4 as described above, or antigenic 
regions or epitopes thereof are also contemplated for use in 
the vaccines, so long as the sequence includes one or both of 
amino acid residues 232 and 300 as Thr andAsp, respectively. 60 
The terms "identity" and "similarity" are know in the art, 
where use of the term "identity" generally refers to a sequence 
comparison based on identical matches between correspond-
ing identical positions in the sequences being compared. 
The term "similarity" refers to a comparison between 65 
amino acid sequences, and takes into account not only iden-
tical amino acids in corresponding positions, but also func-
In one embodiment of the invention, the vaccine recipient 
is a puppy. By "puppy" we mean a young dog that is less than 
about 8 weeks of age. Typically, the vaccine is administered to 
a puppy at an age of e.g. 2-3 weeks, followed by booster doses 
at 4 and 6 weeks. In some embodiments, the vaccine is not 
used after 8 weeks, as after that time, vaccines directed to 
other known circulating viruses may then be employed with-
out interference by maternal antibodies. 
While in some embodiments, the vaccine recipient is a 
puppy, those of skill in the art will recognize that this need not 
always be the case. The vaccine may be administered to a dog 
of any age and to other species of animals ( especially carni-
vores) that are susceptible to infection by parvoviruses, both 
adults and juvenile animals. Examples include but are not 
limited to canids (e.g. wild canids such as wolves, wild dog 
species, coyotes, foxes such as gray, kit and red, etc.], etc.), 
skunks, cats (including domestic cats and kittens, and larger 
species of cats, whether domesticated or wild such as bobcats, 
cougars, lion, tigers, etc.), mink, red panda, etc.; various 
procyonidae, including raccoons, coatis, kinkajous, olingos, 
ringtails and cacomistles, etc. Such animals may be domes-
ticated (e.g. pets), "working" animals (e.g. service animals), 
livestock, animals in the wild, animals in captivity or on 
reserves, in zoos, in shelters, etc., so long as they can benefit 
by administration of the vaccine. 
The immunogenic/vaccine preparations of the present 
invention may be administered by any of many suitable 
means which are well known to those of skill in the art, 
including but not limited to by injection, administered 
parenterally, for example, intramuscularly, subcutaneously, 
intraperitoneally, intradermally or the like, orally via a 
"puppy lollipop" as described above, intranasally, by inges-
tion of a food product containing the antigen, etc. However, in 
preferred a embodiment, the mode of administration to an 
adult recipient is by injection, and, as described above, the 
mode of injection to a juvenile is via a solid preparation that 
dissolves in the mouth upon sucking. The compositions of the 
invention may be administered alone or in combination with 
other medicaments or immunogenic compositions, e.g. as 
part of a multi-component vaccine. Further, administration 
may be a single event, or multiple booster doses may be 
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administered at various timed intervals to augment the 
immune response. In the case of administration to puppies, a 
typical administration regimen would be ( as described above) 
initial administration at e.g. 2-3 weeks of age, followed by 
booster doses at 4 and 6 weeks. Preferably, administration is 
prophylactic, i.e. before exposure to the virus has occurred, or 
is suspected to have occurred, but may also be after the fact, 
i.e. after a known or suspected exposure, or therapeutically, 
e.g. after the occurrence of disease symptoms associated with 
viral infection. 
The invention also provides methods of eliciting an 
immune response in a patient or individual in need thereof, as 
well as methods of vaccinating a patient or individual ( espe-
cially a carnivore such as a juvenile canid, e.g. a puppy) 
against parvovirus infection. The methods include adminis-
tering one or more doses of an immune eliciting preparation 
or a vaccine preparation to the recipient. The amount of the 
dose that is administered is sufficient to elicit an immune 
response, preferably a protective immune response, to the 
antigens encoded by the nucleic acids that are administered. 
Alternatively, in the case of administering one or more amino 
acid sequences as described herein, the immune response is to 
the antigens present in the amino acid sequences. Preferably, 
the immune response is protective and no disease symptoms 
will occur as a result of administration. However, those of 
skill in the art will recognize that many effective vaccine 
compositions cause some relatively minor symptoms upon 
administration, or attenuate without eliminating all symp-
toms of disease once the recipient is infected with a disease 
causing organism. However, the benefits of being protected 
against full-blown disease far outweigh these possibilities. 
In other embodiments, the raccoon parvovirus of the inven-
tion is used as a gene delivery system. The raccoon parvovirus 
(RPV) described herein is an autonomously replicating par-
vovirus (ARP). The use of ARPs as gene delivery vehicles and 
expression vectors has been described (see U.S. Pat. No. 
5,585,254 to Maxwell, et al.). Since the RPV of the invention 
is antigenically non-reactive with sera from dogs vaccinated 
Number 




























with CPV or which have been naturally exposed to CPV, this 
RPV is well-suited for use as a gene vehicle and/or expression 
vector for canines, and also for other species (see below). 
Genetically engineered RPVs are used to carry into a cell of 
5 interest "foreign" or "heterologous" nucleic acid sequences, 
i.e. sequences which do not originate from RPV, but which 
encode and express within the cell of interest, or otherwise 
promote or facilitate expression of, a polypeptide or peptide 
of interest. For example, one or more immunogens may be 
10 
encoded and the RPV may be administered to a subject in 
order to elicit an immune response to the one or more immu-
nogens (e.g. to vaccinate the subject). 
RPV is small, non-enveloped single-stand DNA-contain-
ing virus. Like other autonomous parvoviruses of vertebrates, 
15 
the RPV genome has two open reading frames, ORF! and 
ORF2 flanked by inverted terminal repeats (ITRs) which are 
required for DNA replication (FIG. 4A). Expression of ORF 1 
and OEF2 is driven by promoters P4 and P38, respectively 
(FIG. 4B). ORF! encodes non-structural (NS) proteins NS! 
20 
and NS2, and ORF2 encodes capsid proteins VP-I, VP-2 and 
VP-3 (FIG. 4C). NS! is a multifunctional protein that is 
necessary for viral DNA replication and promoter trans-acti-
vation, such as that which drives transcription ofVP-1 and 
VP-2. NS2 is essential for replication, virus production and 
25 
nuclear egress of progeny virions. Parvovirus particles have 
icosahedral symmetry and are about 20 nm in diameter. The 
particles contain about 50% protein and about 50% DNA, 
with neutralizing epitopes being present on the exposed sur-
face of the particles. 
30 
It is possible to insert heterologous sequences within 
canine parvovirus capsid proteins, e.g. the VP-2 protein, and 
the same or similar strategies are used to genetically engineer 
the RPV of the present invention. (Austin et al., Tropic deter-
minant for canine parvovirus and feline panlenkopenia virus 
35 
functions through the capsid protein VP-2, Journal of General 
Virology (1997), 78, 925-928.) Table 1 lists restriction sites 
located within the gene encoding VP-2. One or more of these 
restriction sites may be used as sites for insertion of foreign 
DNA. 
TABLE 1 
Restriction map ofVP-2 of Raccoon parvovirus. 
[---------Base 5' to Cleavage Sites----------] 
825 1048 1149 
1045 
159 218 455 1065 1611 
64 571 988 1006 1615 
73 472 
1022 
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TABLE I-continued 
Restriction ma:12 ofVP-2 of Raccoon 12arvovirus. 
Number 
Enzyme of Cuts [ --------- Base 5' to Cleavage Sites ---------- ] 
BsaAI 0 
BsaBI 2 1109 1127 
BseMII 2 493 1592 
BsePI 0 












CviJI 10 64 295 483 571 863 988 1006 1059 1615 1627 
CviRI 12 277 313 346 414 517 532 1024 1078 1141 1372 1462 
1546 
Ddel 7 479 581 769 1007 1190 1578 1621 









EeoRII 2 372 1488 
EeoRV 1231 
Esp! 0 









Hhal 2 1098 1515 
Hincll 2 40 282 
Hindm 0 




Mae! 4 680 1738 1745 1799 
Mae!! 945 
Maem 3 321 951 1569 




Msel 22 158 217 281 368 395 443 454 511 658 1064 1259 
1265 1331 1349 1366 1375 1438 1522 1610 1664 1682 
1758 





Neal 3 601 625 705 
Ndel 0 
Nhel 0 
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TABLE I-continued 
Restriction ma:12 ofVP-2 of Raccoon 12arvovirus. 
Number 















ScrFI 2 374 1490 
Sdul 1026 
Seel 4 328 601 625 705 
SexAI 0 













Sspl 2 1257 1701 
Stu! 0 
Sty! 4 328 601 625 705 
Swal 2 159 218 
Taql 0 
Tat! 2 210 759 
Tfil 3 469 1248 1641 
Tse! 3 568 1078 1117 
sp451 0 
Tsp4CI 2 34 462 
TspEI 25 154 160 237 261 317 389 437 730 747 784 879 
926 1310 1328 1409 1423 1482 1495 1518 1565 1600 
1646 1678 1715 1750 
TspRI 0 
Tthll 11 0 




Xholl 4 70 577 714 1305 
XmaIII 0 
Xmnl 0 
Restriction sites that will be particularly useful for inserting 
nuclei acid sequences into the VP-2 gene include EcoRI, 
Hpal, and PstI. This is because these restriction sites are 
commonly engineered in the multiple cloning sites of most 
recombinant vectors. 
Autonomous parvoviruses are generally limited to packag-
ing a total of amount of DNA equal to about 105% of their 
wild DNA content. Thus, preferred transgenes or portions 
thereof (i.e. heterologous or foreign nucleotide sequences, 
nucleic acid sequences which do not naturally occur in par-
voviruses, etc.) for inclusion in the RPV gene delivery 
vehicles of the invention are generally from about 9 to about 
60 nucleotides in length. For example, sequences of about 60 
nucleotides or less ( e.g. about 10, 15, 20, 25, 30, 35, 40, 45, 50 
or 55 nucleotides) can be readily accommodated. Such 
sequences generally encode sequences of interest ( e.g. small 
proteins, polypeptides, peptides, etc.) comprising from about 
3 to about 20 amino acids e.g. about 3, 4, 5, 6, 7, 8, 9, 19, 11, 
12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids. In one 
55 embodiment, peptides up to 12 amino acids encoded by 36 
nucleotides are accommodated by the RPV. However, in other 
embodiments, significantly more nucleic acid sequences are 
inserted by replacing portions of the VP-2 protein by the 
foreign DNA. For example, in some embodiments, from 
60 about 50 to 550 amino acids are replaced, e.g. about 50, 100, 
150,200,250, 300,350,400, 450, 500, or even 550 (the entire 
VP-2 gene) are replaced by foreign DNA, with retention or 
addition of the required inverted repeats. 
Sequences of interest encoded by the heterologous nucle-
65 otide sequences may include, for example, one or more 
epitopes or antigenic regions of interest from a protein of 
interest, examples of which include but are not limited to: 
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surface proteins of important pathogens of dogs, cats and 
other species; cassettes oflinear epitopes of canine distemper 
virus, canine adenovirus and/or canine influenza virus surface 
protein; multiple peptides selected from hemagglutinin of 
canine distemper virus and canine influenza virus; the ami-
nogenic epitope of canine parvovirus; the amino epitope of 
canine adenovirus (derived from the penton protein), etc. 
Additional epitopes of some important canine viruses have 
been defined. (See, for example, Sugai et al, Microbial Immu-
nol. 53(12):667-74, 2009; Jung et al, J Vet Sci. 6(1):21-4, 
2005; Ghosh et al, Immunology l 04(1 ):58-66, 2001; etc.). 
In other embodiments, the encoded polypeptide/peptide 
has a function or properties other than ( or in addition to) that 
of eliciting an immune response, e.g. cytotoxicity to tumor 
cells, targeting properties, etc. 
In some embodiments of the invention, the RVP gene deliv-
ery vehicle may be further genetically engineered to permit 
targeting of the RVP to a cell type or cell types of interest. 
Like other carnivore parvoviruses ( and also rodent arena 
viruses), raccoon parvoviruses enter cells by binding to cell 
surface transferrin receptors (TFR), as illustrated schemati-
cally in FIG. SA. By manipulating and mutating the cognate 
transferrin binding sites of RPV (anti-receptor sites), (e.g. 
proteins VP-1, VP-2 and/or VP-3), it is possible to alter the 
host range of the virus and/or the cell type which the RPV can 
infect. For example, such genetically engineered RPV are 
able to bind to transferrin receptors and infect cells of species 
other than raccoon (including humans), and can thus be used 
20 
make recombinant RPV plasmids. The RPV vectors are har-
vested from cell extracts prepared several days after transfec-
tion. 
Virotherapy for tumors is now being explored (see, for 
5 example, Rommelaere et al, Cytokine & Growth Factor 
Reviews 21:185-195, 2010; and U.S. Pat. No. 7,179,456 to 
Rommelaere et al, the complete contents of which are herein 
incorporated by reference). However, there is a need for novel 
viruses that can carry out the targeted attacks. The RPV of the 
10 
invention can be used in this manner, i.e. as tumor therapy 
agent. The use of the RVP in this manner generally involves 
the identification of a subject with a tumor in which the RVP 
is able to replicate, and administration of the RVP to the 
subject that bears the tumor. Administration may be carried 
out in any suitable manner, including but not limited to intra-
15 venously, by injection directly into the tumor (i.e. intratu-
moral administration), etc. RPV virotherapy is mainly 
intended for a single-administration (e.g. "one-shot") treat-
ment. This is because once the subject ( e.g. a dog) receives the 
RPV, it will respond immunologically by creating antibodies 
20 to the RPV. Thus, the possibility of giving an effective second 
shot is less likely. Thus, the one dose that is administered has 
a very high parvovirus concentration. For example, the dose 
will range from at least about 10 million to 100 million virus 
particles per dose per dose. Only RPV can be administered in 
25 an adult dog to cause no diarrhea and kill residual tumor cells 
in a diffuse tumor. Only RPV (but not, for example, CPV-2 or 
FPLV) can be used at these very high doses and yet cause no 
clinical disease in the recipient, i.e. RPV will not cause diar-
as gene delivery vehicles in species other than canines. Alter-
natively, RPV s with altered host ranges can be identified and 30 
selected during passage of the virus in cells from a variety of 
species. There are generally two ways to achieve targeting 
specificity, transductional targeting and transcriptional tar-
geting. Transductional targeting involves the selective uptake 
rhea in a tumor bearing dog or cat. 
Subjects with tumors which may be treated in this manner 
include but are not limited to, for example, dogs, cats, pet 
minks, raccoons and humans, the therapy being highly effi-
cacious for dogs and cats. The subject may be a juvenile or an 
adult. Types of tumors which may be treated with the RPV of 
35 the invention include but are not limited to: for dogs, histio-
cytic sarcoma (which are diffuse and for which no successful 
treatment is currently available), pancreatic cancers, lympho-
mas, gliomas, and osteosarcoma, etc.; for cats, the tumors 
of the vector into the cells of interest, for example, dividing 
cells of canine cancers, intestinal cells, etc. This may occur by 
genetically modifying the virus to contain and express factors 
necessary for binding to and infecting a cell of interest, e.g. 
ligands (e.g. cognate ligands, which may be proteins) which 
bind receptors located exclusively ( or almost exclusively) on 40 
the surface of the cell of interest, and which cause or permit 
uptake of the virus by the cell of interest. For example, trans-
ductional targeting with an RPV is generally carried out by 
genetically engineering the RPV to express on its outer sur-
face a cognate ligand of a receptor type that is found only on 
the targeted cell. In transcriptional targeting, although the 
transgene may be taken by many different host cells it is 
transcribed only in target cells. Transcriptional targeting with 
listed above and also hepatobiliary tumors, etc. 
In one embodiment, the RPV that is used to treat the tumor 
is genetically engineered to specifically target the tumor cells 
so that viral binding to the tumor cells is selective or, prefer-
ably, specific. This use of the RVP of the invention may also 
be carried out, for example, in adult dogs, since even if they 
45 have been previously vaccinated against CPV, the antibodies 
they carry will not fully neutralize the RPV of the invention. 
The invention also provides diagnostic kits for the detec-
tion of the raccoon parvoviruses described herein. Such kits 
may include oligonucleotide primers specific for amplifying an RPV is generally carried out by including a cell specific 
and/or inducible promoter in the construct to drive expression 
of the heterologous sequences of interest only ( or almost 
exclusively) in the targeted cells. 
A general strategy for preparing autonomous parvovirus 
vectors has been described by Maxwell et al., (Methods 28 
(2002) 168-181), and RPV viral vector production can be 
adapted as described therein, e.g. similarly to production of 
the LuIII vector. Briefly, a productive cell line such as CRFK 
is used. Producer cells (such as the 324K cell line) are trans-
fected with supercoiled forms of a recombinant RPV plasmid 
containing transgene sequences of interest, together with one 
or more plasmids expressing the required helper functions for 
excision, amplification and packaging of the virus particles 
e.g. NS!, NS2, VP!, VP-2, etc. This process is illustrated 
schematically in FIG. SB. Strategies for making recombinant 
plasmids for canine and feline parvoviruses have been 
described (Austin et al., Journal of General Virology (1996), 
77, 1787-1792) and the same or similar strategies are used to 
50 ( e.g. by polymerase chain reaction) the nucleic acid 
sequences disclosed herein. Alternatively, such kits may 
include antibodies ( e.g. monoclonal or polyclonal) that bind 
selectively or specifically to unique antigenic determinants 
displayed by the parvoviruses, e.g. for Asp at position 300 of 
55 the VP-2 protein. Methods of detecting the RPVs are also 
encompassed. Such methods generally involve obtaining a 
biological sample from a subject suspected of being infected 
with an RPV of the invention, and detecting the presence or 
absence of an RPV of the invention in the sample, e.g. using 
60 oligonucleotide primers specific for amplifying ( e.g. by poly-
merase chain reaction) the nucleic acid sequences disclosed 
herein, and/or by using antibodies specific for the RPV s dis-
closed herein. Methods of diagnosing infection of an animal 
with the RPV s ( e.g. MoAb that react with RPV and raccoon 
65 kidney cell culture) using these methods are also provided. 
The foregoing examples serve to illustrate the invention but 
should not be construed as limiting in any way. 




Isolation of a Novel Parvovirus from a Raccoon 
The common North American raccoon (Procyon lotor) is a 
nocturnal onmivore that has adapted well to urban habitats. 
Raccoons prefer to live near river banks that provide shelter 
and food; in urban setting they may interact with dogs and 
cats. Raccoons are susceptible to some diseases that affect 
carnivores, especially canine distemper, rabies, canine aden-
ovirus, leptospirosis, influenza A and parvovirus. There are 
previous reports of the detection and characterization of par-
vovirus from raccoons in Canada (Barker et al., 1983) and the 
USA (Nettles et al., 1980); however, there are no published 
reports in the past two decades. It has also been reported that 
raccoons are not susceptible to canine parvovirus type 2 
(CPV-2) (Appel and Parrish, 1982). However, as disclosed 
herein evidence is provided that suggests that this is not the 
case. Moreover, the present disclosure describes the isolation 
of a parvovirus genetically related to CPV-2 in a rescued 
raccoon at a wildlife rehabilitation facility in the USA. 
22 
tents were inoculated onto cultured Crandall-Reese feline 
kidney (CRFK) cells (ATCC). 
For virus isolation, the sample of intestine was prepared as 
a 10 percent w/v suspension and freeze-thawed once. The 
5 suspension was extracted with an equal volume of chloro-
form. After centrifugation at 10,000 g for five minutes, the 
supernatant was filtered through a 0.22 µm syringe filter. The 
filtrate was inoculated onto CRFK cells approximately 45 
minutes after plating in the flasks. The cells were observed 
10 daily for 5 days, and on the fifth day cytopathology charac-
terized by rounding and detachment of cells was observed. 
The cells were freeze-thawed twice and subjected to ahemag-
glutination test with porcine erythrocytes. The sample 
showed hemagglutinating activity, that parvovirus had repli-
15 cated in the cell culture. The presence of the virus was further 
confirmed by the general parvovirus PCR (Desario et al., 
2005) on the cell culture supernatant, followed by sequencing 
of the amplicon. 
Three independent sequences were obtained from the same 
20 specimen (AR-08071304). All the sequences were the same. 
Two were derived from the fresh sample of intestinal con-
tents, and the third was derived from the isolate cultured in 
CRFK cells. The three sequences were subjected to BLAS TN 
analysis andCLUSTALW analyses (National Center for Bio-
25 technology Information). Based on sequence analysis, the 
raccoon parvovirus was found to be genetically most closely 
related to CP-V2. 
A two-month-old male raccoon was admitted to wildlife 
rehabilitation in Arkansas, USA. The raccoon was clinically 
normal at the time of admission. After 4 weeks, the raccoon 
developed loss of appetite and severe diarrhea. The raccoon 
was treated with enrofloxacin (Baytril, Bayer) administered 
once a day, and fluids were administered subcutaneous. 30 
Despite this treatment, the animal died. Two other raccoons 
had previously died in the same facility one after showing 
similar clinical signs. The raccoon was submitted to the Okla-
homa Animal Disease Laboratory for postmortem examina-
tion. 
To completely sequence the viral protein-2 (VP-2) of the 
raccoon parvovirus, two additional PCR amplifications were 
performed as described by Decaro et al., (2008). The com-
plete VP-2 sequence of the raccoon parvovirus was subjected 
to BLAST analysis. The sequence had highest identity with 
CPV (98 percent); and had an identity of 97 percent with 
isolates of feline panleukopaenia virus, another raccoon par-
35 vovirus (M24005), and miuk enteritis virus (FIG. 6). 
On gross examination, the oral mucosa and sclera were 
pale to white, the abdomen was distended and the perineum 
and anal areas were covered with thin '=y' yellow fluid. 
The animal weighed 1.5 kg and had adequate skeletal muscle 
and body fat stores, consistent with acute death. The stomach 
contents were mucoid yellow with yellow granular material. 
The small intestine was dilated and red, with rough serosa. 
The contents of both the small and large intestines were 
=y, mucoid and yellowish, with yellow material coating a 
smooth glassy mucosa. 
Histopathological examination revealed that the spleen 
was congested and the follicles were depleted oflymphocytes 
with lymphoid necrosis. Diffuse pulmonary edema was evi-
dent in the lungs. Sections of small intestine had widespread 
crypt necrosis with sloughing of the villi and collapse of the 
remaining lamina propria. A few areas revealed scattered, 
large, hyperchromatic regenerating crypt epithelial cells. The 
intestinal luminal surface was coated with fibrin, neutrophils, 
bacteria and some hemorrhage. Immunohistochemistry for 
CPV revealed rare positive signals, which were evaluated as 
equivocal. The microscopic appearance of the intestine was 
consistent with viral enteritis. 
Fresh sections of the intestine and tongue were examined 
by the fluorescent antibody test with monoclonal antibody 
3 B 10 ( fluorescein isothiocynate-labeled anti-CPV conjugate; 
MVRD) (Kapil et al., 2007). Both tissues were found to be 
negative. Based on the histopathological findings, there were 
few enterocytes remaining in the intestine that could have 
contained virus. The general PCR for carnivore parvovirus, as 
developed by Desario et al., (2005), was carried out twice on 
the intestinal contents, and was strongly positive both times. 
To further support the virology findings, the intestinal con-
In experimental studies, raccoons have been found to be 
susceptible to miuk enteritis virus and feline parvovirus 
(Barker et al., 1983 ). The raccoon isolate described here had 
biological and sequence homology with CPV-2. Approxi-
40 mately 500 base pairs of the partial sequence ofVP-2 had 
highest homology (99 percent) with CPV-2. The codons at 
positions 426 and 555 helped classification of the raccoon 
isolate as CPV-2 (Desario et al., 2005). Moreover, codons 564 
and 568 were also consistent with CPV-2 (Truyen et al., 
45 1994). Codon 564 in the raccoon isolate was AGT, as it is in 
canine parvovirus; this codon 564 is AAT in feline parvovirus 
and the previous raccoon isolate (M24005). Codon 568 is 
GGT in both CPV-2 and the present raccoon isolate; however, 
it is GCT in feline parvovirus and the previous raccoon isolate 
50 (M24005). 
Similarly, based on the amino acid sequence ofVP-2, the 
raccoon parvovirus may be considered to be a unique variant 
of CPV-2. At amino acid position 80 ofVP-2, the raccoon 
isolate had arginine, the same as VP-2 from CPV isolates; in 
55 contrast, feline parvovirus has lysine at amino acid position 
80. At amino acid position 87, the raccoon isolate had a 
leucine residue, like the variants ofCPV-2, CPV-2a and CPV-
2b; both FPV and CPV-2 have methionine at amino acid 
position 87. At amino acid position 93, the raccoon isolate had 
60 asparagine, like all CPVs, while FPVhas lysine at this amino 
acid position. At amino acid position 101, the raccoon isolate 
had threonine, similar to CPV-2a and CPV-2b; both FPV and 
CPV-2 had isoleucine at amino acid position 101. At amino 
acid position 103, the raccoon parvovirus had alanine, like 
65 CPV-2a and CPV-2b, whereas FPV and CPV-2 have valine at 
amino acid position 103. The raccoon parvovirus had threo-
nine at amino acid position 232, serine at amino acid position 
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Due to the likely interactions of raccoons with companion 
animals in urban areas of the USA, this finding is epidemio-
logically significant. Based on a published survey from 
Canada (Barker et al., 1983), raccoons may be frequently 
297 and aspartic acid at amino acid position 300; FPV and 
CPV-2 have alanine at amino acid position 300, while CPV-2a 
and CPV-2b have glycine at amino acid position 300. At 
amino acid position 305, the raccoon isolate had aspartic acid, 
like FPV and CPV-2; CPV-2a and CPV-2b have tyrosine at 
this amino acid position. The raccoon parvovirus had aspar-
agine at amino acid position 426, like FPV, CPV-2, and CPV-
5 exposed to CPV-2. In the study of Barker et al., (1983), 25 of 
out of 112 raccoons (22.4 percent) tested in Canada were 
seropositive; with most animals positive at hemagglutination-
inhibition titres equal to or greater than 1:256. Raccoons have 
also been implicated in the spillover ofFPV to zoo animals in 2a. At amino acid position 555, the raccoon isolate had valine, 
like most CPV genotypes and FPV; however, CPV-2a has 
isoleucine at amino acid position 555. At amino acid position 
564, the raccoon isolate had serine, like all CPV isolates; FPV 
has asparagine at this amino acid position. At amino acid 
position 5 68, the raccoon parvovirus had glycine, like CPV-2; 
FPV has alanine at this amino acid position. Thus, based on 
15 
the complete VP-2 sequence of the raccoon parvovirus isolate 
(CAR-08071304), it was considered to be a unique genetic 
variant ofCPV-2. A summary of these differences is shown in 
FIG. 7. 
10 
urban environments (Junge et al., 2007). Raccoons may be 
exposed to CPV-2 due to their omnivorous nature and feeding 
habits. The role of urban raccoons in the transmission of 
CPV-2 to other species requires further investigation. There is 
Notably, amino acid residue 232 is Thr in the raccoon 
20 
isolate and amino acid residue 300 is Asp. These two amino 
acid residues in the VP-2 protein of RPV are thus distinct 
from the VP-2 proteins of all other known CPV isolates and 
may be responsible for the unique properties ( e.g. antibody 
reactivity) of this RPV. In particular, substitution of amino 
25 
acid residue 300 from Gly (uncharged, side chain=H) to Asp 
(negative charge at neutral pH, side chain=CH2Coo-) alters 
the antigenic properties of the virus. Without being bound by 
theory, it is likely that this change also affects the receptor 
binding properties of the virus. 
30 
The previous raccoon isolate M24005 was isolated in the 
USA in 1979. The present isolate was antigenically different 
from current circulating CPV-2 isolates in USA, based on its 









(Kapil et al., 2007). Virus isolation-positive tissue was nega-
tive by direct fluorescent antibody testing. On the basis of the 
55 
histological findings, few enterocytes were present lining the 
intestines when the raccoon died. The lack of reactivity with 
A3 B 10 was not surprising, because this monoclonal antibody 
reacts with a major antigenic domain of CPV-2 (Wikoff et al., 
1994 ). The intestinal contents were negative for parasitic ova 
by direct examination and fecal floatation test. The intestinal 60 
contents were negative for parasitic ova by direct examination 
and the faecal flotation test, and negative on ELISA for 
Clostridium difficile toxin. Streptococcus dysgalatiae subspe-
cies equisimilis and Streptococcus uberis were isolated from 
a sample of lymph node by routine bacteriological examina- 65 
tion. Secondary bacterial contaminants or their toxins may 
have contributed to the death of the raccoon. 
no published evidence of natural CPV-2 infection in rac-
coons. However, based on a hemagglutination assay, CPV-2 
was implicated in a captive raccoon in the USA based upon 
hemagglutination of porcine erythrocytes at pH 7 .2 (Nettles 
et al., 1980); the genome sequence was not determined in that 
study. 
Example 2 
Reactivity of Carnivore Parvoviruses with 
Commercially Available Monoclonal Antibodies 
Testing of the new isolate was carried out using four addi-
tional commercially available antibodies, CPVl-24, CPVl-
13 and CPVl-5 (Custom Monoclonal Antibodies, Sacra-
mento, Calif.). These canine parvovirus-2 antibodies are 
commercially available for routine diagnosis of canine par-
vovirus-2. The results are presented in Table 2. As can be 
seen, the antibodies react similarly with CPV, FPLV and RPV. 
This shows that some immunogenic epitopes are conserved 
among these viruses. 
TABLE2 
Antibody testing of three additional raccoon isolates 
CPV Monoclonal Antibodies 
Assigned# CPVl-2 CPVl-24 CPVl-13 CPVl-5 
CPV-2c 08060974 ± 
CPV-2c 08090386 ± 
CPV-2c 07030244 ± 
CPV-2c 07080797 ± 
CPV-2c 07051347 + 
CPV-2b 08070185 ± 
CPV-2b 07030847 ± 
FPV 08120386 ± 
FPV 08061339 
RPV,pH7.2 08071304 ± 
RPV,pH 6.5 08071304 ± 
Example 3 
Reactivity of Three Other Raccoon Parvoviruses 











In addition to the Arkansas raccoon parvovirus 08071304 
described above, three additional parvoviruses of raccoon 
origin but from Illinois were tested with respect to reactivity 
with the 3B10 MoAb (VMRD, WA) using fluorescent anti-
body testing. 3B10 MoAb is specific for CPV-2 and is fre-
quently used to identify and/or diagnose parvovirus infection 
in dogs. All three viruses tested negative with 3B10 MoAb. 
Thus, as was the case for the RPV described in Examples 1 
and 2, no epitopes of these three additional raccoon viruses 
were recognized by this CPV-2 MoAb antibody. 
US 8,734,808 B2 
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These results demonstrate that these three parvoviruses, 
like RPV, also have a mutation at amino acid position 300 of 
VP-2, since these intestinal tissue samples did not react with 
the 3B10 MoAb, which is known to react with an epitope that 
includes the amino acid at position 300 in other parvoviruses. 5 
Inverse-Complement for 10071191-C, nucleotide positions 
1216 to 1774 (556 nucleotides in length): 
(SEQ ID NO, 7) 
TCAGGAAGATATCCAGAAGGAGATTGGATTCAAAATATTAACTTTAAC 
Example 4 
Sequencing of Gene Encoding The VP-2 Proteins of 
the Three Additional Raccoon Parvoviruses 
The gene encoding the VP-2 protein of each of the three 
viruses described in Example 3 was partially sequenced and 
the results are presented below. 
Inverse-Complement for 10071191-A, nucleotide positions 
1216 to 1773 (i.e. 557 nucleotides in length): 













Inverse-Complement for 10071191-B, nucleotide positions 
1214 to 1779 (565 nucleotides in length): 

























These are partial VP-2 sequences of RPV from Chicago, 
Ill. Thus, amino acid residue 300 was not sequenced. How-
ever, the lack of reactivity with 3B 10 MoAb ( see Example 3) 
indirectly supports that the mutation at amino acid position 
300 is also present in these viruses. Aligmnent of the four 
sequences (namely the full length 08071304 with the three 
30 partial sequences 10071191-1,2,3) and revealed some differ-
ences. The first significant change is that at nucleotide 1216, 
of 08071304 has an "A", whereas all three newly identified 
RPVs (10071191A, Band C) have a "T". All four sequences 
are identical from nucleotides 1217 to 1261. However, at 
35 nucleotide position 1262 of 10071191-B, there is a "G" 
instead of an "A" which is present in the other 3 sequences. 
From nucleotides 1263 through 1268, all the sequences are 
identical. However, at nucleotide position 1269, sequence 
10071191-B has a "G" insteadofa "T"whichis present in the 
40 other three sequences. Similarly, at nucleotide positions 1272 
and 1273, 10071191-B has "GG" instead of"AA" which is 
present in the other three sequences. From nucleotides 1274 
through 1292 all four sequences are identical. However, at 
nucleotide position 1293 all sequences have an "A" but 
45 
10071191-B has a "G". From nucleotide 1294 through 1300 
all sequences are identical, but then at nucleotide position 
1301, 10071191-B has a "G" rather than an "A". From nucle-
otide 1302 through 1349 all sequences are identical, but at 
nucleotide position 1350 all sequences have a "T' but 
10071191-2 has a "G". From nucleotide position 1351 all 
50 sequences are identical up to nucleotide position 1706. 
Based on this we conclude that one isolate, 10071191-B, 
has a base point mutation to "G" in several locations of the 
VP-2 gene. 
Experiments conducted with respect to culturing these 3 
55 new RPVs showed that 10071199-A can be propagated in cell 
culture, and that 10071199-C is highly cytopathic in the 




Phylogenetic Comparison of the New Raccoon 
Parvovirus Isolates 0808294, 10071191-1, 
10071191-2 and 10071191-3 with Other Known 
Carnivore Parvoviruses 
To construct a more extensive phylogenetic tree of carni-
vore parvoviruses, the full length sequence encoding the 
US 8,734,808 B2 
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VP-2 protein of new raccoon parvovirus isolate 0808294, the 
partial sequences encoding the VP-2 protein of raccoon iso-
lates 10071191-1, 10071191-2 and 10071191-3 VP-2, and 
several otherCPV-2 parvovirus sequences (available from the 
National Center for Biotechnology Information (NCBI) web- 5 
site) were compared. All sequences were first converted to 
PASTA formats and then aligned using the CLUSTAL/W 
program of the MEGA 4.1 software. The tree was constructed 
using Bootstrap analysis and the hierarchical clustering 
method UPGMA (Unweighted Pair Group Method with 10 
Arithmetic Mean). 
The results are depicted in FIG. 8, which shows the NCBI 
GI numbers of each isolate. As can be seen, the Arkansas RPV 
(08071304) clusters with the well characterized canine par-
voviruses. Thus, evolutionarily it is a canineparvovirus-2 like 15 
virus. 
Example 6 
Basic Local Alignment Search Tool (BLAST) 20 
Analysis of Pull Length 08071304 RPVVP-2 
Sequence 
The 1801 nucleotide sequence of08071304 RPVVP-2 was 
analyzed using BLAST analysis. The results showed that this 25 
sequence exhibits high homology with other carnivore par-
vov1ruses. 
The first 7 highest identities (99%) were with canine par-
voviruses. Surprisingly several 98% identities were obtained 
with feline panluekopaenia. There was 98% identity score 30 
with a raccoon parvovirus (M24005.1) and there was also 
98% identity with mink enteritis virus. This is unusual for 
parvovirus VP-2 sequences, in that such high levels of iden-
tity are not usually observed amongst several different carni-
vore parvoviruses. Normally, a canine parvovirus aligns and 35 
shows high identity only with other canine parvoviruses, 
feline panleukopaenia shows the highest identity with other 
feline panleukopaenia viruses, etc. It thus appears that 
08071304 is a chimeric carnivore parvovirus. This observa-
tion is further supported by the amino acid comparisons 40 
shown in FIG. 7. In the past, carnivore parvoviruses were easy 
to classify based on the amino acid sequence ofVP-2. Inter-
estingly, the RPV (08071304) of the invention does not fol-
low the linear VP-2 DNA convention and rules. At some 
places, as shown in FIG. 7, the amino acid that is at a critical 45 
epitope is like that ofFPV or MEY (e.g. at amino acid posi-
tion 305). However, at amino acid position 93, it is like CPV. 
Thus, 08071307 RPV is unique genetically, antigenically and 
with respect to amino acid sequence. This virus would likely 
provide a common carnivore parvovirus for overcoming 50 
maternal derived immunity in several species. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 7 
<210> SEQ ID NO 1 
<211> LENGTH, 1800 
<212> TYPE, DNA 
<213> ORGANISM: Raccoon parvovirus 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1274) .. (1274) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 1 
atgagtgatg gagcagttca accagacggt ggtcaacctg ctgtcagaaa tgaaagagct 
acaggatctg ggaacgggtc tggaggcggg ggtggtggtg gttctggggg tgtggggatt 
tctacgggta ctttcaataa tcagacggaa tttaaatttt tggaaaacgg atgggtggaa 
atcacagcaa actcaagcag acttgtacat ttaaatatgc cagaaagtga aaattataga 
agagtggttg taaataattt agataaaact gcagttaacg gaaacatggc tttagatgat 
actcatgcac aaattgtaac accttggtca ttggttgatg caaatgcttg gggagtttgg 
tttaatccag gagattggca actaattgtt aatactatga gtgagttgca tttagttagt 
tttgaacaag aaatttttaa tgttgtttta aagactgttt cagaatctgc tactcagcca 
ccaactaaag tttataataa tgatttaact gcatcattga tggttgcatt agatagtaat 
aatactatgc catttactcc agcagctatg agatctgaga cattgggttt ttatccatgg 
aaaccaacca taccaactcc atggagatat tattttcaat gggatagaac attaatacca 
tctcatactg gaactagtgg cacaccaaca aatacatacc atggtacaga tccagatgat 
gttcaatttt atactattga aaattctgtg ccagtacact tactaagaac aggtgatgaa 
tttgctacag gaacattttt ttttgattgt aaaccatgta gactaacaca tacatggcaa 
acaaatagag cattgggctt accaccattt ctaaattctt tgcctcaatc tgaaggagat 
actaactttg gtgatatagg aattcaacaa gataaaagac gtggtgtaac tcaaatggga 
aatacaaact atattactga agctactatt atgagaccag ctgaggttgg ttatagtgca 
ccatattatt cttttgaggc gtctacacaa gggccattta aaacacctat tgcagcagga 
cgggggggag cgcaaacaga tgaaaatcaa gcagcagatg gtgatccaag atatgcattt 
ggtagacaac atggtcaaaa aactaccaca acaggagaaa cacctgagag atttacatat 
atagcacatc aagatacagg aagatatcca gaaggagatt ggattcaaaa tattaacttt 
aaccttcctg taanaaatga taatgtattg ctaccaacag atccaattgg aggtaaaaca 
ggaattaact atactaatat atttaatact tatggtcctt taactgcatt aaataatgta 
ccaccagttt atccaaatgg tcaaatttgg gataaagaat ttgatactga cttaaaacca 
agacttcatg taaatgcacc atttgtttgt caaaataatt gtcctggtca attatttgta 
aaagttgcgc ctaatttaac aaatgaatat gatcctgatg catctgctaa tatgtcaaga 
attgtaactt actcagattt ttggtggaaa ggtaaattag tatttaaagc taaactaaga 
gcctctcata cttggaatcc aattcaacaa atgagtatta atgtagataa ccaatttaac 
tatgtaccaa gtaatattgg aggtatgaaa attgtatatg aaaaatctca actagcacct 
agaaaattat attaacatac ttactatgtt tttatgttta ttacatatca actagcacca 
<210> SEQ ID NO 2 
<211> LENGTH, 1752 

































<213> ORGANISM: Raccoon parvovirus 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1274) .. (1274) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 2 
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-continued 
atgagtgatg gagcagttca accagacggt ggtcaacctg ctgtcagaaa tgaaagagct 
acaggatctg ggaacgggtc tggaggcggg ggtggtggtg gttctggggg tgtggggatt 
tctacgggta ctttcaataa tcagacggaa tttaaatttt tggaaaacgg atgggtggaa 
atcacagcaa actcaagcag acttgtacat ttaaatatgc cagaaagtga aaattataga 
agagtggttg taaataattt agataaaact gcagttaacg gaaacatggc tttagatgat 
actcatgcac aaattgtaac accttggtca ttggttgatg caaatgcttg gggagtttgg 
tttaatccag gagattggca actaattgtt aatactatga gtgagttgca tttagttagt 
tttgaacaag aaatttttaa tgttgtttta aagactgttt cagaatctgc tactcagcca 
ccaactaaag tttataataa tgatttaact gcatcattga tggttgcatt agatagtaat 
aatactatgc catttactcc agcagctatg agatctgaga cattgggttt ttatccatgg 
aaaccaacca taccaactcc atggagatat tattttcaat gggatagaac attaatacca 
tctcatactg gaactagtgg cacaccaaca aatacatacc atggtacaga tccagatgat 
gttcaatttt atactattga aaattctgtg ccagtacact tactaagaac aggtgatgaa 
tttgctacag gaacattttt ttttgattgt aaaccatgta gactaacaca tacatggcaa 
acaaatagag cattgggctt accaccattt ctaaattctt tgcctcaatc tgaaggagat 
actaactttg gtgatatagg aattcaacaa gataaaagac gtggtgtaac tcaaatggga 
aatacaaact atattactga agctactatt atgagaccag ctgaggttgg ttatagtgca 
ccatattatt cttttgaggc gtctacacaa gggccattta aaacacctat tgcagcagga 
cgggggggag cgcaaacaga tgaaaatcaa gcagcagatg gtgatccaag atatgcattt 
ggtagacaac atggtcaaaa aactaccaca acaggagaaa cacctgagag atttacatat 
atagcacatc aagatacagg aagatatcca gaaggagatt ggattcaaaa tattaacttt 
aaccttcctg taanaaatga taatgtattg ctaccaacag atccaattgg aggtaaaaca 
ggaattaact atactaatat atttaatact tatggtcctt taactgcatt aaataatgta 
ccaccagttt atccaaatgg tcaaatttgg gataaagaat ttgatactga cttaaaacca 
agacttcatg taaatgcacc atttgtttgt caaaataatt gtcctggtca attatttgta 
aaagttgcgc ctaatttaac aaatgaatat gatcctgatg catctgctaa tatgtcaaga 
attgtaactt actcagattt ttggtggaaa ggtaaattag tatttaaagc taaactaaga 
gcctctcata cttggaatcc aattcaacaa atgagtatta atgtagataa ccaatttaac 
tatgtaccaa gtaatattgg aggtatgaaa attgtatatg aaaaatctca actagcacct 
agaaaattat at 
<210> SEQ ID NO 3 
<211> LENGTH, 599 
<212> TYPE, PRT 
<213> ORGANISM: Raccoon parvovirus 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 































<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 3 
32 
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-continued 
Met Ser Asp Gly Ala Val Gln Pro Asp Gly Gly Gln Pro Ala Val Arg 
1 5 10 15 
Asn Glu Arg Ala Thr Gly Ser Gly Asn Gly Ser Gly Gly Gly Gly Gly 
20 25 30 
Gly Gly Ser Gly Gly Val Gly Ile Ser Thr Gly Thr Phe Asn Asn Gln 
35 40 45 
Thr Glu Phe Lys Phe Leu Glu Asn Gly Trp Val Glu Ile Thr Ala Asn 
50 55 60 
Ser Ser Arg Leu Val His Leu Asn Met Pro Glu Ser Glu Asn Tyr Arg 
65 70 75 80 
Arg Val Val Val Asn Asn Leu Asp Lys Thr Ala Val Asn Gly Asn Met 
85 90 95 
Ala Leu Asp Asp Thr His Ala Gln Ile Val Thr Pro Trp Ser Leu Val 
100 105 110 
Asp Ala Asn Ala Trp Gly Val Trp Phe Asn Pro Gly Asp Trp Gln Leu 
115 120 125 
Ile Val Asn Thr Met Ser Glu Leu His Leu Val Ser Phe Glu Gln Glu 
130 135 140 
Ile Phe Asn Val Val Leu Lys Thr Val Ser Glu Ser Ala Thr Gln Pro 
145 150 155 160 
Pro Thr Lys Val Tyr Asn Asn Asp Leu Thr Ala Ser Leu Met Val Ala 
165 170 175 
Leu Asp Ser Asn Asn Thr Met Pro Phe Thr Pro Ala Ala Met Arg Ser 
180 185 190 
Glu Thr Leu Gly Phe Tyr Pro Trp Lys Pro Thr Ile Pro Thr Pro Trp 
195 200 205 
Arg Tyr Tyr Phe Gln Trp Asp Arg Thr Leu Ile Pro Ser His Thr Gly 
210 215 220 
Thr Ser Gly Thr Pro Thr Asn Thr Tyr His Gly Thr Asp Pro Asp Asp 
225 230 235 240 
Val Gln Phe Tyr Thr Ile Glu Asn Ser Val Pro Val His Leu Leu Arg 
245 250 255 
Thr Gly Asp Glu Phe Ala Thr Gly Thr Phe Phe Phe Asp Cys Lys Pro 
260 265 270 
Cys Arg Leu Thr His Thr Trp Gln Thr Asn Arg Ala Leu Gly Leu Pro 
275 280 285 
Pro Phe Leu Asn Ser Leu Pro Gln Ser Glu Gly Asp Thr Asn Phe Gly 
290 295 300 
Asp Ile Gly Ile Gln Gln Asp Lys Arg Arg Gly Val Thr Gln Met Gly 
305 310 315 320 
Asn Thr Asn Tyr Ile Thr Glu Ala Thr Ile Met Arg Pro Ala Glu Val 
325 330 335 
Gly Tyr Ser Ala Pro Tyr Tyr Ser Phe Glu Ala Ser Thr Gln Gly Pro 
340 345 350 
Phe Lys Thr Pro Ile Ala Ala Gly Arg Gly Gly Ala Gln Thr Asp Glu 
355 360 365 
Asn Gln Ala Ala Asp Gly Asp Pro Arg Tyr Ala Phe Gly Arg Gln His 
370 375 380 
Gly Gln Lys Thr Thr Thr Thr Gly Glu Thr Pro Glu Arg Phe Thr Tyr 
385 390 395 400 
Ile Ala His Gln Asp Thr Gly Arg Tyr Pro Glu Gly Asp Trp Ile Gln 
405 410 415 
Asn Ile Asn Phe Asn Leu Pro Val Xaa Asn Asp Asn Val Leu Leu Pro 
420 425 430 
34 
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-continued 
Thr Asp Pro Ile Gly Gly Lys Thr Gly Ile Asn Tyr Thr Asn Ile Phe 
435 440 445 
Asn Thr Tyr Gly Pro Leu Thr Ala Leu Asn Asn Val Pro Pro Val Tyr 
450 455 460 
Pro Asn Gly Gln Ile Trp Asp Lys Glu Phe Asp Thr Asp Leu Lys Pro 
465 470 475 480 
Arg Leu His Val Asn Ala Pro Phe Val Cys Gln Asn Asn Cys Pro Gly 
485 490 495 
Gln Leu Phe Val Lys Val Ala Pro Asn Leu Thr Asn Glu Tyr Asp Pro 
500 505 510 
Asp Ala Ser Ala Asn Met Ser Arg Ile Val Thr Tyr Ser Asp Phe Trp 
515 520 525 
Trp Lys Gly Lys Leu Val Phe Lys Ala Lys Leu Arg Ala Ser His Thr 
530 535 540 
Trp Asn Pro Ile Gln Gln Met Ser Ile Asn Val Asp Asn Gln Phe Asn 
545 550 555 560 
Tyr Val Pro Ser Asn Ile Gly Gly Met Lys Ile Val Tyr Glu Lys Ser 
565 570 575 
Gln Leu Ala Pro Arg Lys Leu Tyr His Thr Tyr Tyr Val Phe Met Phe 
580 585 590 
Ile Thr Tyr Gln Pro Ser Thr 
595 
<210> SEQ ID NO 4 
<211> LENGTH, 584 
<212> TYPE, PRT 
<213> ORGANISM: Raccoon parvovirus 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (425) .. (425) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 4 
Met Ser Asp Gly Ala Val Gln Pro Asp Gly Gly Gln Pro Ala Val Arg 
1 5 10 15 
Asn Glu Arg Ala Thr Gly Ser Gly Asn Gly Ser Gly Gly Gly Gly Gly 
20 25 30 
Gly Gly Ser Gly Gly Val Gly Ile Ser Thr Gly Thr Phe Asn Asn Gln 
35 40 45 
Thr Glu Phe Lys Phe Leu Glu Asn Gly Trp Val Glu Ile Thr Ala Asn 
50 55 60 
Ser Ser Arg Leu Val His Leu Asn Met Pro Glu Ser Glu Asn Tyr Arg 
65 70 75 80 
Arg Val Val Val Asn Asn Leu Asp Lys Thr Ala Val Asn Gly Asn Met 
85 90 95 
Ala Leu Asp Asp Thr His Ala Gln Ile Val Thr Pro Trp Ser Leu Val 
100 105 110 
Asp Ala Asn Ala Trp Gly Val Trp Phe Asn Pro Gly Asp Trp Gln Leu 
115 120 125 
Ile Val Asn Thr Met Ser Glu Leu His Leu Val Ser Phe Glu Gln Glu 
130 135 140 
Ile Phe Asn Val Val Leu Lys Thr Val Ser Glu Ser Ala Thr Gln Pro 
145 150 155 160 
Pro Thr Lys Val Tyr Asn Asn Asp Leu Thr Ala Ser Leu Met Val Ala 
165 170 175 
Leu Asp Ser Asn Asn Thr Met Pro Phe Thr Pro Ala Ala Met Arg Ser 
36 
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-continued 
180 185 190 
Glu Thr Leu Gly Phe Tyr Pro Trp Lys Pro Thr Ile Pro Thr Pro Trp 
195 200 205 
Arg Tyr Tyr Phe Gln Trp Asp Arg Thr Leu Ile Pro Ser His Thr Gly 
210 215 220 
Thr Ser Gly Thr Pro Thr Asn Thr Tyr His Gly Thr Asp Pro Asp Asp 
225 230 235 240 
Val Gln Phe Tyr Thr Ile Glu Asn Ser Val Pro Val His Leu Leu Arg 
245 250 255 
Thr Gly Asp Glu Phe Ala Thr Gly Thr Phe Phe Phe Asp Cys Lys Pro 
260 265 270 
Cys Arg Leu Thr His Thr Trp Gln Thr Asn Arg Ala Leu Gly Leu Pro 
275 280 285 
Pro Phe Leu Asn Ser Leu Pro Gln Ser Glu Gly Asp Thr Asn Phe Gly 
290 295 300 
Asp Ile Gly Ile Gln Gln Asp Lys Arg Arg Gly Val Thr Gln Met Gly 
305 310 315 320 
Asn Thr Asn Tyr Ile Thr Glu Ala Thr Ile Met Arg Pro Ala Glu Val 
325 330 335 
Gly Tyr Ser Ala Pro Tyr Tyr Ser Phe Glu Ala Ser Thr Gln Gly Pro 
340 345 350 
Phe Lys Thr Pro Ile Ala Ala Gly Arg Gly Gly Ala Gln Thr Asp Glu 
355 360 365 
Asn Gln Ala Ala Asp Gly Asp Pro Arg Tyr Ala Phe Gly Arg Gln His 
370 375 380 
Gly Gln Lys Thr Thr Thr Thr Gly Glu Thr Pro Glu Arg Phe Thr Tyr 
385 390 395 400 
Ile Ala His Gln Asp Thr Gly Arg Tyr Pro Glu Gly Asp Trp Ile Gln 
405 410 415 
Asn Ile Asn Phe Asn Leu Pro Val Xaa Asn Asp Asn Val Leu Leu Pro 
420 425 430 
Thr Asp Pro Ile Gly Gly Lys Thr Gly Ile Asn Tyr Thr Asn Ile Phe 
435 440 445 
Asn Thr Tyr Gly Pro Leu Thr Ala Leu Asn Asn Val Pro Pro Val Tyr 
450 455 460 
Pro Asn Gly Gln Ile Trp Asp Lys Glu Phe Asp Thr Asp Leu Lys Pro 
465 470 475 480 
Arg Leu His Val Asn Ala Pro Phe Val Cys Gln Asn Asn Cys Pro Gly 
485 490 495 
Gln Leu Phe Val Lys Val Ala Pro Asn Leu Thr Asn Glu Tyr Asp Pro 
500 505 510 
Asp Ala Ser Ala Asn Met Ser Arg Ile Val Thr Tyr Ser Asp Phe Trp 
515 520 525 
Trp Lys Gly Lys Leu Val Phe Lys Ala Lys Leu Arg Ala Ser His Thr 
530 535 540 
Trp Asn Pro Ile Gln Gln Met Ser Ile Asn Val Asp Asn Gln Phe Asn 
545 550 555 560 
Tyr Val Pro Ser Asn Ile Gly Gly Met Lys Ile Val Tyr Glu Lys Ser 
565 570 575 
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Gln Leu Ala Pro Arg Lys Leu Tyr 
580 
<210> SEQ ID NO 5 
<211> LENGTH, 557 
<212> TYPE, DNA 
<213> ORGANISM, Raccoon parvovirus 
<400> SEQUENCE, 5 
tcaggaagat atccagaagg agattggatt caaaatatta actttaacct tcctgtaaca 60 
aatgataatg tattgctacc aacagatcca attggaggta aaacaggaat taactatact 120 
aatatattta atacttatgg tcctttaact gcattaaata atgtaccacc agtttatcca 180 
aatggtcaaa tttgggataa agaatttgat actgacttaa aaccaagact tcatgtaaat 240 
gcaccatttg tttgtcaaaa taattgtcct ggtcaattat ttgtaaaagt tgcgcctaat 300 
ttaacaaatg aatatgatcc tgatgcatct gctaatatgt caagaattgt aacttactca 360 
gatttttggt ggaaaggtaa attagtattt aaagctaaac taagagcctc tcatacttgg 420 
aatccaattc aacaaatgag tattaatgta gataaccaat ttaactatgt accaagtaat 480 
attggaggta tgaaaattgt atagaaaaat ctcaactagc acctagaaaa ttatattaac 540 
aacttagcta gtcttat 557 
<210> SEQ ID NO 6 
<211> LENGTH, 565 
<212> TYPE, DNA 
<213> ORGANISM, Raccoon parvovirus 
<400> SEQUENCE, 6 
ggtcaggaag atatccagaa ggagattgga ttcaaaatat taactttagc cttccggtgg 60 
caaatgataa tgtattgctg ccaacaggtc caattggagg taaaacagga attaactata 120 
ctaatatatt taatacgtat ggtcctttaa ctgcattaaa taatgtacca ccagtttatc 180 
caaatggtca aatttgggat aaagaatttg atactgactt aaaaccaaga cttcatgtaa 240 
atgcaccatt tgtttgtcaa aataattgtc ctggtcaatt atttgtaaaa gttgcgccta 300 
atttaacaaa tgaatatgat cctgatgcat ctgctaatat gtcaagaatt gtaacttact 360 
cagatttttg gtggaaaggt aaattagtat ttaaagctaa actaagagcc tctcatactt 420 
ggaatccaat tcaacaaatg agtattaatg tagataacca atttaactat gtaccaagta 480 
atattggagg tatgaaaatt gtatagaaaa attctcaaac tagcacctag aaaattatat 540 
aacaacttta cttctggtgg gcggg 565 
<210> SEQ ID NO 7 
<211> LENGTH, 556 
<212> TYPE, DNA 
<213> ORGANISM, Raccoon parvovirus 
<400> SEQUENCE, 7 
tcaggaagat atccagaagg agattggatt caaaatatta actttaacct tcctgtaaca 60 
aatgataatg tattgctacc aacagatcca attggaggta aaacaggaat taactatact 120 
aatatattta atacttatgg tcctttaact gcattaaata atgtaccacc agtttatcca 180 
aatggtcaaa tttgggataa agaatttgat actgacttaa aaccaagact tcatgtaaat 240 
gcaccatttg tttgtcaaaa taattgtcct ggtcaattat ttgtaaaagt tgcgcctaat 300 
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ttaacaaatg aatatgatcc tgatgcatct gctaatatgt caagaattgt 
gatttttggt ggaaaggtaa attagtattt aaagctaaac taagagcctc 
aatccaattc aacaaatgag tattaatgta gataaccaat ttaactatgt 
attggaggta gaaaattgta tagaaaaatc tcaactagca cctagaaaat 
acttagctag gcgtat 
I claim: 
1. A raccoon parvovirus (RPV) comprising the character-
istics ofi) Parvovirus-2 (Raccoon) ofATCC NO. PTA-11400 
or ii) progeny of Parvovirus-2 (Raccoon) of ATCC NO. PTA~ 15 
11400, wherein said characteristics include that said RPV 
comprises a nucleic acid encoding a VP-2 protein, said 
nucleic acid comprising nucleotide sequence SEQ ID NO: 1. 
2. An immunogenic composition comprising a nucleic acid 
comprising the nucleotide sequence SEQ ID NO: 1, or a 20 
portion of SEQ ID NO: 1; wherein said portion of SEQ ID 
NO: 1 encodes an antigenic region of a VP-2 protein com-
prising both amino acid residue Thr at position 232 and amino 
acid residue Asp at position 300 of SEQ ID NO: 3, wherein 
said nucleic acid is present in a killed or attenuated parvovirus 25 
virion or low passage raccoon parvovirus (RPV). 
3. The immunogenic composition of claim 2 wherein said 
killed parvovirus virion comprises the characteristics of i) 
Parvovirus-2 (Raccoon) having the ATCC NO. PTA-11400 
or ii) progeny of Parvovirus-2 (Raccoon) of ATCC NO. PTA~ 30 
11400, wherein said characteristics include that said RPV 
comprises a nucleic acid encoding a VP-2 protein, said 






ID NO: 1, or a portion of SEQ ID NO: 1, wherein said portion 
of SEQ ID NO: 1 encodes an antigenic region of a VP-2 
protein comprising both amino acid residue Thr at position 
232 and amino acid residue Asp at position 300 of SEQ ID 
N0:3. 
7. The method of claim 6, wherein said nucleic acid is 
present in a killed or attenuated parvovirus virion or low 
passage RPV in a killed or attenuated parvovirus virion. 
8. The method of claim 7, wherein said killed parvovirus 
virion comprises the characteristics of i) Parvovirus-2 (Rac-
coon) having the ATCC NO. PTA-11400,or ii) progeny of 
Parvovirus-2 (Raccoon) ofATCC NO. PTA-11400, wherein 
said characteristics include that said RPV comprises a nucleic 
acid encoding a VP-2 protein, said nucleic acid comprising 
the nucleotide sequence SEQ ID NO: 1. 
9. The method of claim 7, wherein said attenuated parvovi-
rus virion is present in a solid carrier suitable for supralingual 
dissolution. 
10. The method of claim 6, wherein said immunogenic 
composition is suitable for subcutaneous administration. 
11. The method of claim 9, wherein said animal is a puppy. 
12. An expression vector comprising a nucleotide sequence 1. 
4. The immunogenic composition of claim 2, wherein said 
attenuated parvovirus virion is present in a solid carrier suit-
able for supralingual dissolution. 
5. The-immunogenic composition of claim 2 wherein said 
immunogenic composition is suitable for 'subcutaneous 
administration. 
35 encoding the amino acid sequence of SEQ ID NO: 3, or a 
portion of SEQ ID NO: 3; wherein said portion of SEQ ID 
NO: 3 i~ an m_itigen_ic region of a VP-2 protein comprising 
both ammo acid residue Thr at position 232 and amino acid 
6. A method of eliciting an immune response in an animal 
against parvovirus infection, comprising the step of adminis-
!ering to sa)d an)mal an immunogenic composition compris-
mg a nucleic acid comprising the nucleotide sequence SEQ 
40 
residue Asp at position 300 of SEQ ID NO: 3, 
wherein said expression vector is a recombinant expression 
vector or a killed or attenuated viral vector. 
13. The expression vector of claim 12, that is a recombinant 
viral expression vector. 
* * * * * 
